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ABSTRACT 
 
 
 
BACKGROUND: Access to antiretroviral therapy (ART) for HIV positive patients has brought 
hope and a chance to a healthier longer life with improved quality of life (QoL). In this study we 
explored the difference in health related quality of life (HRQoL) between participants eligible for 
ART and those not yet eligible for ART as per the 2015 South African HIV treatment guidelines. 
We also considered the impact of ART access on HRQoL and the effect of employment status and 
education level. The study was conducted at one tertiary hospital and two primary health care 
facilities in Johannesburg, South Africa. 
AIM: To determine how access to ART for HIV-positive patients with higher CD4 cell counts 
affected HRQoL and the role of socioeconomic status. The objectives of the study were to 
determine if there was a significant difference in HRQoL between the two groups of patients, 
eligible for ART and those not yet eligible for ART at a CD4 cell count cut off of 500cells/mm
3 
and to examine HRQoL at initiation of ART and again two to three months post ART initiation. 
METHOD: A cross-sectional study compared baseline measurements of HIV-positive patients 
eligible and not eligible for ART, while the cohort eligible for ART were followed up after two to 
three months on ART. HRQoL was measured using the EQ-5D questionnaire (which determined 
the index score and VAS score, as objective and subjective measures for HRQoL, respectively), 
and, socioeconomic and clinical data were collected using an adapted version of the South African 
household survey questionnaire. 
RESULTS: A total of 105 participants were enrolled in the study. The baseline group had a 
median age of 36 (IQR 30-44)   years, about 70% were female, 89.62% had an education level of 
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Grade 12 or higher, about 67% were either employed or self-employed and 50% had a CD4 count 
of 500cells/mm
3 
and higher. The baseline group was further divided into those 46 participants not 
eligible for ART and those 60 who were eligible and thus initiated on ART. Participants initiating 
on ART were significantly older than those not eligible for ART with median ages of 38 (IQR 
32-46) and 34(IQR 27-43) years, respectively (p=0.0084). The group not yet eligible for ART 
comprised of mostly women (91.30%) versus the eligible group that comprised of only about half 
of women (53.33%) (p< 0.001). Both groups had comparable levels of education and income.    As  
expected  the  group  not  yet  eligible  for  ART  had  a significantly higher CD4 cell count 
compared to the ART eligible group with median of 697.50 (IQR 589-900) and 213.50 (IQR 80-
387.50) cells/mm
3  
respectively, (p< 0.001). 
The HRQoL for the entire baseline group was most affected by pain and discomfort, followed by 
depression and anxiety, amounting to 40.57% and 23.58% of participants, respectively. The only 
significant difference between the ART eligible and non-ART eligible groups were that the ART 
group initially experienced more problems with usual activities (18.33%) than the non-ART group 
(2.00%), (p=0.037). However, the VAS score indicated that at baseline ART group had a 
significantly higher median of 90 (IQR 76.50-99) while non-ART group scored median 66.50 (IQR 
60-80); (p < 0.001). 
At two to three months follow up of the group that started ART, there was one patient that was lost 
to follow up. The total number of ART group changed from 60 to 59. The HRQoL for ART group 
at two to three month follow up improved significantly except for usual activities.  Mobility 
improved from 86.67% to 98.31% (p=0.011), pain/discomfort increased from 60% to 83% (p= 
0.005), depression/anxiety rose from 78% to 84% (p = 0.008).   Median VAS score increased 
from 90 to 98 (p < 0.001). 
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In the univariate analysis males were 9% CI (0.86-0.97) (p=0.004) less likely to experience 
significant problems with mobility. With higher education thus above grade twelve the percentage 
change in the incident rate of not experiencing problems with mobility is an increase of 75% (CI 
1.02-1.13) (p=0.005) for every unit increase in education. The ART naïve group was 11% (CI 
1.01-1.20) (p=0.025) less likely to experience problems with mobility and 21% (CI 1.06-1.38) 
(p=0.004) less likely to experience problems with pain/discomfort. 
The multivariate analysis did not find a difference in the HRQoL outcomes in mobility and usual 
activities. There was nevertheless an 11% (CI 0.76-0.93) (p=0.001) less likelihood that the ART 
naïve group would experience problems with anxiety/depression as compared to the group that 
was eligible for ART. 
 
 
 
CONCLUSION/RECOMMENDATIONS: Access to ART does bring about improvement in 
HRQoL after 2-3 months of ART as indicated by the index score and the VAS score. Higher 
education level (above grade 12) and employment were associated with better HRQoL. Further 
studies should be done to look at the impact of ART on HRQoL for patients with higher CD4 
counts over an extended period than in this study. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
South Africa has the world’s biggest Human Immunodeficiency Virus (HIV) epidemic with an 
estimated 7.03 million people living with HIV in 2016 (Statistics South Africa, 2016). In 2015 
there were about 3.2 million people on antiretroviral treatment (ART) in South Africa (Kahn, 
2016). Eligibility criteria for ART in an HIV-positive individual are determined through measuring 
CD4 cell count and/or determining World Health Organisation (WHO) stage. According to (World 
Health Organisation, 2007), the HIV stages were developed for resource poor settings where 
laboratory services may not be available as well as to assist in the scale up of ART initiation. The 
classification of these stages are based on clinical symptoms, they are stages 1 to 4 and are defined 
by specific clinical conditions or symptoms. 
ART was initially rolled out in the South African public sector in 2004 with eligibility criteria to 
initiate ART at CD4 cell counts of less than or equal to 200 cells/mm³ and/or WHO stage 4 
regardless of CD4 count (National Department of Health South Africa, 2004). By 2005, 85000 
South Africans had been initiated on ART (Simelela and Venter, 2014). By 2011, ART coverage 
in South Africa was 75% of individuals eligible for ART (UNAIDS, 2014). This was accomplished 
through many interventions including the commitment of government to provide ART to 80% of 
eligible HIV positive people including foreign nationals (Simelela and Venter, 2014). 
In 2013 the eligibility criteria to initiate ART changed to CD4 counts of less than or equal to 
350cells/mm³ and/or patients with WHO stage 3 and 4 regardless of CD4 count. The guidelines 
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also made provision for patient with tuberculosis co-infection regardless of CD4 cell count and 
pregnant women regardless of CD4 count until they deliver after which ART will be stopped 
(option B) (WHO, 2014). The new criteria decreased ART coverage to 55% of eligible adults 
(Simelela and Venter, 2014). However, HIV related mortality decreased from 320 000 per annum 
in 2010 to 140 000 per annum in 2014 (Kahn, 2016. The HIV prevalence however remained high 
at 21.5% in women and 18.3% in males between the ages of 15 to 49 years. (Statistics South Africa, 
2016). 
In January 2015 the eligibility criteria for ART initiation changed again to a CD4 count of less 
than or equal to 500cells/mm³ and/or WHO stage 3 or higher regardless of CD4 count, including 
tuberculosis co-infection regardless of CD4 cell count, patients with active hepatitis B co- infection 
and lifelong ART for pregnant women. This change reduced coverage further to 42% in 2015 
(UNAIDS, 2015). This can be attributed to an even higher number of patients eligible for ART 
within resource restricted health care facilities. 
Access to ART for HIV positive patients has brought hope and a chance to a healthier and longer 
life with improved quality of life (QoL). Moller (2007) suggests that with the introduction of ART, 
the prospects for South Africans to live a long and happy life have become a reality. With 
sentiments like these, it is therefore important to measure HRQoL in HIV infected patients 
especially in the era of ART (Louwagie et al., 2007). 
Health related quality of life (HRQoL) is a multidimensional concept that includes global health 
perspective, symptom status, functional status, biological and physical variables, individual and 
environmental characteristics and general health perceptions as suggested by Wilson and Cleary 
(1995). However, the QoL of the individual is intertwined with factors permeating their families 
and society such as gender equality, education level and   other socio-economic variables. 
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Socioeconomic status is often measured as combination of education, income and occupation, 
therefore socioeconomic status often determines access to ART. (American Psychological 
Association, 2016). In South Africa “rates of new infections among young women aged 15-24 
were more than four times greater than that of men in the same age range. Poverty, the low status 
of women and gender-based violence have been cited as reasons for the disparity in HIV 
prevalence between men and women in South Africa”. (UNAIDS, 2014). 
Education has long been identified as having a key role to play in reducing HIV-related risk and 
vulnerability, and mitigating the impact of the epidemic on affected individuals and communities 
(Aggleton et al., 2011). A study done in Malawi in 2009 where young girls were given money to 
stay in school not only reduced drop-out rates but also protected them from contracting HIV 
(UNAIDS, 2010). 
The impact of HIV and AIDS on employment and hence income can be devastating. The impact 
of absenteeism and death on the economy is still evident even though the magnitude is not very 
clear currently due to lack of information disclosure by companies and confidentiality issues (Vos, 
2005). The huge bearing of HIV on social aspects however cannot be ignored as it has brought 
about death, child-headed households and missed enrolment into schools hence missed 
opportunities to education (Vos, 2005). 
Nannungi, Wagner and Ghosh-Dastidar (2013) demonstrated that loss of work and  income after 
HIV diagnosis was common, however after initiating  treatment, patients were able to work again 
and earn an income. ‘Work performance improved and absenteeism decreased, with the most 
dramatic changes occurring in the first three months of treatment and then leveling off.’  (Beard et 
al., 2009). 
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1.1 Problem statement 
 
With the change in HIV treatment guidelines in 2015 where patients were initiated on ART 
treatment with higher CD4 counts (350-500 cell/mm³ and >500 cell/mm³), had better health 
conditions and were not as sick as when the last studies on QoL were done. (Lifson et al., 2016). 
There are few studies that have assessed the effect of higher CD4 counts on HRQoL in South 
Africa. These patients are physically healthy and therefore one would expect that they would be 
employed, be productive and involved in the labor force. It is therefore important to measure 
HRQoL of these patients and actually examine how ART affects their HRQoL, and compare this 
with patients that have not yet started ART treatment. One of the studies that looked at the initiation 
of ART at a higher CD4 count was the Strategic Timing of Antiretroviral Therapy (START) trial, 
this study demonstrated the importance of starting ART early (Lifson et al., 2016). 
In September 2016 South Africa adopted universal test and treat (UTT) which means eligibility 
for ART of any and all HIV-positive people. With the wide scale up of ART and South Africa 
adopting the universal test and treat approach it is important to track how the impact of ART 
translates into improved QoL and well-being for these patients. 
1.2 Research questions 
 
Is there a difference in QoL between patients eligible for ART versus patients not yet eligible for 
ART if the CD4 count cut off is 500cells/mm
3
? 
Does access to ART improve quality of life two to three months post therapy initiation at CD4 
counts higher than 350cells/mm
3
? 
Does access to ART for patients with higher CD4 counts of 500cells/mm
3
 and their socio-
economic status affect QoL among people living with HIV? 
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1.3 The research hypotheses are: 
 
1.3.1 Research hypothesis 1 
 
Null hypothesis (H01): There is no difference in QoL between patients eligible for ART versus 
those not yet eligible for ART. 
Alternative hypothesis (H11): There is a difference in QoL between patients eligible for ART 
versus those not yet eligible for ART. 
1.3.2 Research hypothesis 2 
 
Null hypothesis (H0 2): Access to ART does not improve QoL two to three months post ART 
initiation. 
Alternative hypothesis (H1 2): Access to ART improves QoL two to three months post ART 
initiation. 
1.3.3 Research hypothesis 3 
 
Null hypothesis (H0 3): Access to ART for patients with CD4 counts higher than 350cells/ mm
3  
does not lead to improved QoL.  
Alternative hypothesis (H1 3): Access to ART for patients with CD4 counts higher than 350cells/ 
mm
3  
does lead to improved QoL. 
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1.4 Primary aim and objectives 
 
The aim of the study was thus to determine how access to treatment for patients with higher CD4 
counts influences their HRQoL and the influence of socioeconomic status such as employment 
status, income and education level. 
The objectives of the study were: 
 
 To determine if there was a significant difference in HRQoL between the two groups of 
patients, eligible for ART and those not yet eligible. 
 To examine QoL at initiation of therapy and again two to three months post initiation of 
ART. 
 To investigate the role of socio-economic status on QoL. 
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CHAPTER 2 
 
 
 
 
LITERATURE REVIEW 
 
 
There are different instruments that measure quality of life. These include generic and specific 
instruments (Skevington and O’Connel, 2003). The generic instruments are patient-focused 
developed to be suitable across all diseases, medical interventions and also across a large 
population area (Coons et al., 2000). Specific instruments look at concerns of a patient’s particular 
disorder, (Skevington and O’Connel, 2003) and they are designed to be relevant to certain 
interventions or subpopulations (Coons et al., 2000). The reliability and validity of two instruments 
above is of significant importance to ensure that indeed treatment outcomes and hence QoL are 
appropriately measured because according to Skevington and O’Connel (2003) “conclusions about 
how QoL is affected by HIV remain equivocal, in part due to problems with reliable and valid 
measurement”. A significant number of studies  (Louwagie et al. 2007;  Nglazi et al. 2014; Stangl 
et al. 2007; Abera et al. 2010) has shown an improvement in HRQoL after the initiation of 
antiretroviral treatment (ART) and that education and income level have a positive effect on 
HRQoL (Table 2.1). 
The EuroQol health questionnaire (EQ-5D) was developed by EuroQol Group which consisted of 
a multidisciplinary research team from Europe, North America, Africa, Asia, Austria and New 
Zealand. It was designed to be self-administered and short enough to be used in conjunction with 
other measures; it takes a few minutes to complete as stated by EuroQol Group (2009). It is a 
generic measure. The tool has two sections, namely the EQ-5D from which the EQ-5D-5L index 
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score is calculated and the visual analogue scale (VAS) score (EQ-VAS). The EQ-5D section is 
divided into five domains which include mobility, self-care, usual activities, pain or discomfort and 
anxiety or depression. Each domain has five levels which are: no problem, slight problem, moderate 
problem, severe problem and unable to perform. The value sets derived from the EQ- 5D can be 
used to deduce the overall health score for each patient, which is referred to as the index score (a 
full health score is equal to 1). The index score can be determined using the EQ- 5D-5L crosswalk 
index value calculator version 2, which has value sets that are representative sample of the general 
population this is found on the EuroQol website (EuroQol Group, 2009), this is an objective 
measure. The second section is EQ-VAS which is a record of the patient’s self-rated health status 
on a scale of 0 to 100, this is a subjective measure. 
The following three studies by Jelsma et al. (2005), Louwagie et al. (2007) and Nglazi et al. (2014) 
conducted in South Africa used the EQ-5D tool to indicate that access to ART does bring about 
improved QoL. In a cohort study conducted in Cape Town, South Africa by Jelsma et al. (2005), 
the eligibility criteria  for ART was CD4 level of  <200 cell/mm³. They demonstrated a significant 
improvement in HRQoL across scores recorded at baseline, one, 6 and 12 months on ART in 117 
participants. It also proved that patients with HIV in resource poor countries can have improved 
HRQoL due to access to ART. Improvement was evident in all domains of the EQ-5D (p<0.01) 
(the study did not calculate each patient’s index score and therefore was not used in this study) and 
EQ-VAS scores (p<0.01). However, they did not indicate how WHO stage 3 and stage 4 affected 
the HRQoL of the study participants. 
A cross-sectional study by Louwagie et al. (2007) measured HRQoL in HIV-positive patients in 
the Free State province of South Africa. The eligibility criteria for ART was CD4 <200 cell/mm³. 
It compared the HRQoL of 268 patients that have been initiated on ART for two months to 103
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patients that were ART naïve. Patients on ART had significantly higher VAS scores and EQ-5D 
index scores compared to ART naïve patients. Additionally the study also looked at socioeconomic 
status such as income, employment status and gender and how these impacted on HRQoL. The 
results indicated that unemployed patients in both groups had lower VAS scores and EQ-5D index 
scores (p = 0.018). Income did not show any positive effect on HRQoL and this was explained by 
the fact that most participants were receiving social grants. Women had higher VAS scored 
compared to men (p = 0.021) indicating higher perceived HRQoL and this was explained by the 
fact that women seek health care earlier before they develop advanced disease. The study did not 
look at clinical predictors such as a CD4 count and viral load or WHO stage. Unlike the study by 
Jelsma et al. (2005) that only used the VAS scores, the results from EQ-5D domains were also used 
to gather the overall QoL of participants. 
A cross sectional study by Nglazi et al. (2014) examined HRQoL in patients with HIV attending 
public sector antiretroviral services in Cape Town. It compared the HRQoL of 468 patients 
initiated on ART to 435 patients who were ART naïve. The ART eligibility was CD4 count ≤350 
cell/mm³. The key findings in this study were that the treatment group had a significantly better 
HRQoL than the ART naïve group, which concurred with the findings of Louwagie and colleagues 
(2007). Similarly, in a later study by Louwagie et al. (2007), Nglazi and colleagues (2014) also 
observed that HRQoL was in fact positively affected by availability of income in the form of 
employment and this was significant (p= 0.003). They concluded that there was an association 
between low CD4 counts in ART naïve patients and low VAS score citing poor QoL. The study 
by Nglazi et al., (2014) had a good sample size of 903 participants and hence the results of the 
study could be generalized to the population in similar setting of the study population and it 
demonstrated the positive impact of higher CD4 count on HRQoL. 
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The next five studies by Stangl et al. (2007), Mwesigire et al. (2015), Rueda et al. (2011), Harding 
et al. (2014) and Stangl et al. (2012) used the Medical Outcomes Study (MOS- HIV)  tool to 
evaluate HRQoL. This tool has been previously validated in sub-Saharan African populations by 
Harding et al. (2014) and it is an objective measure calculated by combining the Physical Health 
Score (PHS) and Mental Health Score (MHS). It has a 35- item QoL scale that addresses 10 health 
dimensions: overall health, physical function, role function, social function, cognitive function, 
pain, mental health, fatigue, health distress, and QoL (Stangl et al., 2007). 
A cohort study conducted in Uganda by Stangl et al. (2007) measured HRQoL across scores 
recorded at baseline, and every three months until 12 months on ART of 710 female and 237 male 
participants. The ART eligibility criteria was CD4 less than 200 cell/mm³. Stangl et al. (2007) 
examined trends and predictors which could be classified into three categories: clinical (CD4 
count, viral load, WHO stage, presence of symptoms); psychosocial (social support, presence of 
depressive symptoms) and sociodemographic (age, employment, financial dependency, education, 
gender). Patients that were financially dependent on others, unemployed, had CD4 counts of less 
than 250cell/mm³ and high viral loads reported poor QoL at baseline. Once ART was initiated and 
CD4 cell count increased there was an improvement in QoL, supporting the theory that access to 
ART as well as improvements in CD4 cell count positively influence QoL. Financial dependence 
on others (p = 0.001) and primary education as compared to post primary education (p = 0.019) 
negatively affected QoL at ART initiation but financial dependence alone had a negative effect 
even at 12 months follow up (p = 0.001). There were two limitations to the study: lack of a control 
group to compare with, and it considered only patients with CD4 counts less than 250cells/mm³. 
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Another prospective cohort study conducted in Uganda by Mwesigire et al. (2015) measured 
HRQoL across scores recorded at baseline, three and six months of two groups of participants. 
One group of 640 patients was initiated on ART at baseline while the other group of 634 patients 
remained ART naïve. Mwesigire et al. (2015) looked at the relationship between CD4 count and 
QoL and the influence of change in HIV guidelines in 2013, WHO recommending initiation of 
ART at CD4 cell counts of less than 350cell/mm³. Most patients were initiated at higher CD4 
counts and they were usually healthier. The authors could not however establish a relationship 
between improved CD4 count and improved QoL on patients taking ART versus ART naïve 
patients. Therefore unlike other studies like Nglazi et al. (2014), this study did not find any 
relationship between change in CD4 cell count among patients on ART and QoL. Mwesigire and 
colleagues (2015) associated this finding with the fact that patients initiating on ART in the study 
had significantly higher CD4 counts compared to other studies done before due to  change in ART 
initiation guidelines. Therefore, higher CD4 count meant positive QoL. However, education level 
and income were found to be related to QoL. The authors discovered that low education thus 
primary education and below as well as income below $60 per month were negatively associated 
with QoL. The large sample size of 1274 was a great strength of the study. This was the first study 
to look at higher CD4 counts and QoL in sub-Saharan Africa. 
A cross sectional study conducted in Toronto, Canada by Rueda et al. (2011) measured HRQoL 
 
361 HIV-positive participants. Rueda et al. (2011) examined the relationship between employment 
status and HRQoL. The eligibility criteria for ART was CD4 count less than 200cells/mm³. The 
major finding was that employment is strongly associated with a good HRQOL (p<0.001). The 
study did not collect substantial information on income and therefore could not demonstrate that 
employment certainly has far more impact on QoL than the actual income because it has been 
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proven that employed people reported higher QoL relative to unemployed people (Blalock et al., 
2002). 
A cross-sectional study conducted in East Africa by Harding et al. (2014) looked at QoL and well-
being among 1337 HIV-positive outpatients initiating on ART with WHO guidelines 
recommending ART to be commenced at CD4 less 200cell/mm³. They observed the relationship 
between more education (diploma and above) (p=0.003), CD4 count above 200cell/mm³ (p<0.001) 
as well as wealth (p<0.001) and improved QOL. In this study CD4 cell count was collected from 
clinic records, one important limitation that is very common in clinical care was lack of consistent 
recording of clinical data such as CD4 count, this affected the overall results of the study. 
A prospective cohort study conducted in rural Uganda by Stangl et al. (2012) measured HRQoL 
across scores recorded at baseline, and every three months until 12 months on ART of 947 
participants. Eligibility criteria for ART initiation was CD4 cell count less 200cells/mm³. Like 
previous studies they discovered a correlation between improved HRQoL and post primary 
education (p < 0.001) as well as income from farming, wages and trade (p < 0.001). Participants 
with no education or primary education and were dependent on others as source of income scored 
low on physical and mental health summary indicating poor HRQoL. Furthermore participants 
with low CD4 counts (less than 50cells/mm³) had lower scores as well. The same was also 
identified with patients with viral loads higher or equal to 5 log10copies/ml. 
Another tool used for measuring HRQoL is a generic measure called Short Form-36 Health Survey 
(SF-36) which has been translated into many languages and is therefore widely used.  It is a patient 
rated instrument that includes: physical function (PF), social function (SF), role physical (RP), role 
emotional (RE), mental health (MH), vitality (VT), bodily pain (BP) and general health (GH). Two 
scores can be generated, these are mental-health component summary score (MHS) and physical-
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health component summary score (PHS) as elaborated by Abera et al. (2010). 
A cross-sectional study conducted in central and Southern Ethiopia by Abera et al. (2010) looked 
at QoL of 422 participants on ART for at least three years. The eligibility criteria used for ART 
initiation was CD4 count less than 200cells/mm³. The key findings were: patients with CD4 counts 
above 200cells/mm³ (p<0.001), on ART longer than 12 months (p<0.005), who attained a 
secondary school education and were employed, were associated with a better QoL. The primary 
limitation of the study was that there was no control group or baseline data before ART initiation 
to compare to or prove that ART was indeed responsible for improved QoL. 
A cross sectional study conducted in Malawi by Fan et al. (2011) compared the QoL of 267 HIV- 
infected patients on ART and 598 non- HIV infected patients. The eligibility criteria used for ART 
initiation was CD4 counts less than 200cells/mm³. Besides SF-36 QoL, they also collected data on 
needs assessments (nutrition, religion, counseling exercise etc.) and socioeconomic status.  The 
majority of HIV-positive patients in this study (98%) completed secondary school and were 
employed (87.4%). HIV-positive patients with CD4 cell counts less than 200cells/mm³ 
(p=0.0148), and with WHO stages 3 and 4 (p=0.0006) demonstrated lower scores on QoL, which 
highlighted the relationship between clinical indicators and QoL. This study also found a positive 
relationship between QoL and employed participants compared to unemployed participants 
(p<0.0001). Moreover most (72.7%) of the participants were women which was indicative of 
increased access to ART to women than men. 
Mûnene and Ekman. (2014) evaluated the extent to which HRQoL in people living with HIV is 
associated with duration of ART in Kenya in a cross sectional study of 421 participants on ART
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for at least one month. The eligibility criteria for ART were CD4 count less than 350cells/mm³. The 
finding was that patients on ART for longer duration reported lower HRQoL due to treatment 
fatigue, adverse drug reactions and reduced engagement with healthcare workers who seems to give 
more attention to newly diagnosed patients. They discovered that higher education (college and 
above) (p≤0.05) and paid employment (income above 10,000 KES (Kenyan shilling)) (p≤0.05) were 
associated with better HRQoL. There was no association between baseline WHO stage and HRQoL 
(p≤0.05). 
World Health Organization QoL Instrument for HIV infected patients (WHOQOL-HIV-Brief) was 
developed by WHO to measure QoL specifically in HIV infected patients. It is available for low 
income countries and was validated for cross-cultural usage. It has 31 items and 6 domain scores 
and these are used to represent a person’s subjective perception of their own QoL in these domains: 
physical, psychological, level of independence, social relationship, physical environment and 
spirituality (Friend-du Preez and Peltzer, 2010). The following six studies by Deribew et al. (2013), 
Friend-du-Preez and Peltzer (2010), Peltzer (2012), Tesfay et al. (2015), Ayodele et al. (2014) and 
Igumbor et al. (2013) used this tool to assess QoL. 
A prospective cohort study in Ethiopia by Deribew et al. (2013) evaluated changes in QoL as 
compared at baseline and 6 months in 465 participants on ART without TB and 124 participants 
on ART and on TB treatment in all the 6 domains related to QoL. The eligibility criteria for ART 
were CD4 count less than 350cells/mm³. There was a significant improvement in HRQoL 
(p=0.000) after 6 months on ART and/or TB therapy. No CD4 counts were recorded for this study 
due to missing data on clinical records. 
A cross-sectional study in public hospitals in Kwazulu-Natal, South Africa by Friend-du-Preez 
and Peltzer (2010) looked at HIV symptoms and HRQoL prior to initiation of ART in 618
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participants. Participants who received disability grants (27%) reported higher QoL than those not 
receiving any form of income (p<0.001). They reasoned that patients with higher education (grade 
12 and above) had better QoL (p<0.001) but the authors did not explain if this was linked to income. 
The majority of participants in this study were unemployed (60.3%), receiving financial assistance 
in the form of government grants (27%) and those that did not have income. Income influenced 
their perceived QoL negatively (p<0.001). 
A prospective cohort study in Kwazulu-Natal, South Africa by Peltzer (2012) looked at changes 
in HRQoL in 735 participants prior to ART initiation, 519 participants after 6 months of ART, 557 
participants after 12 months of ART and 499 participants after 20 months on ART. The eligibility 
criteria for ART were CD4 count less than 200cells/mm³. In this study Peltzer discovered that QoL 
improved in patients on ART. For those that had income in the form of wages HRQoL was affected 
positively (p = 0.000). Employed participants also reported significant improved HRQoL (p = 
0.001) compared to the unemployed participants. Participants with grade 12 and above level of 
education reported better HRQoL compared to education level of grade 11 and below (p=0.04). 
The association of improved QoL and clinical outcomes such as CD4 cell counts of more than or 
equal to 350cells/mm³ mirrored results from other studies conducted in South Africa such as a 
study by Nglazi et al. (2014). This was one of the longest studies which followed patients prior to 
and after ART initiation and gives a better perspective on some of the significant effects on QoL 
over a longer period of time. 
Tesfay et al. (2015) did a comparative cross-sectional study on gender differences in HRQoL in 
five different health institutions in Mekelle Town, Northern Ethiopia with 253 male participants 
and 253 female participants on ART for more than three months. The eligibility criteria for ART 
was CD4 count less than 200cells/mm³.   The findings indicated that women scored lower than 
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males on all domains (p = 0.037). Being illiterate (p < 0.005) and earning a monthly income less 
than $83.75 (p < 0.001) were closely related to poor QoL in both genders. 
A cross-sectional study in Nigeria by Ayodele et al. (2014) looked at HRQoL of 491 participants 
on ART. Participants with CD4 counts above 350cells/mm³ had higher scores in all QoL domains 
(p = 0.001). They did not find any gender differences in all domains of QoL, and they ascertained 
that participants with no education or primary education only reported better QoL in all domains 
as compared to secondary and tertiary education (p=0.002). The authors thought this could be 
brought about the fact that educated people know the consequences of the disease and how it 
affects their lives and hence the negative impact on QoL. 
A comparative cross sectional study in South Africa by Igumbor et al. (2013) compared the level 
of CD4 count, viral load and HRQoL between 311 ART naïve participants and 331 participants on 
ART for 12 months. The eligibility criteria for ART initiation was CD4 count less than 
200cells/mm³. Participants on ART for 12 months had a better QoL compared to treatment naïve 
patients (p = 0.000). Participants on ART had higher CD4 counts (>500 cells/mm
3
) than treatment 
naïve patients (less than 200cells/mm
3
) and the QoL score was higher with rise in CD4 cell count. 
The following studies used various tools to measure QoL. A cohort study in Johannesburg, South 
Africa by Rosen et al. (2010) looked at symptoms, general health as well as normal activity and 
employment using an instrument designed for the study. A cohort of 855 patients initiated on ART 
(616 have been on ART for less than six months), and 210 pre- ART was interviewed and followed 
up for three years. At baseline the cohort had a total of 1065 participants, 449 of whom were not 
yet on ART and 616 were on ART for less than 6 months. By month 12, 607 participants had been 
followed up, 234 were lost to follow up, 75 were transferred out and 53 died. 
 
 
 
 
http://etd.uwc.ac.za
26  
The guidelines during the time of study were access to ART for CD4 less than 200cells/mm
3. 
Interviews were conducted at the time participants presented to the clinic either for medical follow 
up or on medication collection. The results indicated that symptoms (fatigue, pain, nausea and skin 
problems) improved drastically after ART initiation (p=0.000).  According to the study, ART does 
in fact bring about improved QoL and the improvement in all outcomes was sustained over 3 years. 
For some outcomes the increase was seen in the second and third year.  Lost to follow up was very 
high (42%). 
A cross-sectional descriptive survey in Lebanon was conducted by Abboud et al. (2010) on 41 
participants on ART for an unspecified period to determine the impact of HIV on QoL using the 
multidimensional quality of life HIV (MQoL-HIV) tool. The eligibility criteria for ART initiation 
was CD4 count less than 200cells/mm³. An interesting finding was that participants who had 
education level up to primary school had significantly higher HRQoL compared to those with 
university qualifications (p=0.001). These findings were similar to that of Ayodele et al. (2014) 
and both authors came to the conclusion that educated people know the consequences of the 
disease hence it affected their HRQoL negatively. The small sample size of 41 patients limits the 
study to be generalized to the overall Lebanese people living with HIV.  The instrument used to 
measure QoL was never validated in the study population before. 
Abasiubong et al. (2010) assessed QoL in people living with HIV in Niger Delta region, Nigeria 
in a cohort study of 309 participants using HIV/AIDS-Targeted Quality of life (HAT-QoL) 
questionnaire. Data was collected at baseline only, it was not stated whether patients were on ART 
or not and for what period of time. The authors established that females (61.8%) displayed lower 
QoL compared to males (54%) (p <0.01). Access to ART is still a challenge since guidelines still 
limit treatment initiation to CD4 counts of less than or equal to 200cells/mm
3
. 
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Sixty percent of males and 70% of females had financial constraints due to the lack of employment 
and subsequent income. This therefore contributed to poor QoL. 
The following four studies are literature reviews of QoL: 
 
A recent literature review of 303 studies by Skevington and O’Connel (2003) looked at instruments 
used to measure QoL in HIV. The inclusion criteria were studies that used generic instruments of 
QoL as well as HIV- specific instruments. Instruments that were not self- report measures were 
excluded. The authors agreed that socio-economic impact is critical in the care of people living 
with HIV therefore social support such as social grants and feeding schemes are crucial as part of 
their clinical care. Therefore QoL instruments should encompass social and environmental issues 
(stigma and access to care) in order to be relevant. Choosing the right instrument to measure QoL 
is also crucial as this will depend on the study population. Some guidelines in choosing the right 
instruments include ensuring validity and reliability, on the intended use of the instrument. 
A review of 8 cohort studies was undertaken by Jin et al. (2014) to analyze changes in QoL of 
people living with HIV. The inclusion criteria were: it must be a cohort study, patients should be 
initiated on ART at baseline and followed up more than twelve weeks. The studies they reviewed 
confirmed that QoL of patients initiated on ART did improve especially at the beginning of 
treatment. Most studies did not show any relationship between QoL and CD4 cell count, and time 
since the patient was diagnosed. Patients that had CD4 counts of less than 200 cell/mm³ had no 
improved QoL despite ART initiation. However, the fact that studies use different instruments to 
measure QoL cannot be ignored and it brings about disparity in the results.  This  is  because  QoL 
is  a  subjective  experience  that  is  affected  by many factors.  The majority of study locations in 
this literature review were in developing countries making it very relevant in this review. 
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A review by Oguntibeju (2012), examined the effect and benefits of ART on people living with 
HIV based on studies done in developed and developing countries. The author ascertained that 
income was related positively to QoL. The studies also showed the relationship between a higher 
level of education and better QoL (Oguntibeju, 2012). This is in contrast with finding by Abboud 
et al. (2010) who established that university level of education brought about lower HRQoL 
compared to elementary education, while Ayodele et al. (2014) concluded that no education 
translated to better HRQoL. It was apparent in the studies that patients with CD4 cell counts of 
above 300 cells/mm
3 
had a greater QoL. 
 
Robberstad and Olsen (2010) focused on the HRQoL of people living with HIV in sub-Saharan 
Africa in a literature review that focused on 29 articles. The review also looked specifically on 
studies that used the EQ-5D questionnaires which were used in 9 out of the 29 articles. The review 
indicated the EQ-5D is indeed a suitable instrument to measure HRQoL in Africa. Even though 
three of the studies were from South Africa, it is not enough and it is indicative of the significant 
lack of data or research in South Africa on effectiveness of the ART program despite it being 
deemed successful. From these publications it was clear that patients on ART had improved QoL 
compared to patients not yet initiated on ART as they reported amongst others, increased CD4 
count, less symptoms, ability to earn a living and better viral load suppression (Igumbor et al. 
2013; Nglazi et al. 2014). Most studies above indicated a relationship between access to ART and 
improved QoL, but there is still not enough research to indicate relationship between access to 
ART and QoL especially for patients with higher CD4 counts. 
Table 2.1 (page 29) Comparison of sixteen studies‟ on HIV-positive patients either on 
antiretroviral treatment (ART) or not, comparing tools used to measure HRQoL, study design, 
number of 
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HRQoL measurements and intervals between measurements, sample size and groups, and, the 
primary conclusions in terms of influence on HRQoL. 
 
Table 2.1 Comparison of 16 studies 
Author QoL 
measure 
Study design Number of 
QoL 
measurement  
and intervals 
Location Samp
le size 
Main conclusions 
Jelsma et 
al. 2005 
EQ-5D 
and VAS 
Cohort study Four 
measurement s 
at baseline, 1, 
6 and 12 
months 
Cape 
Town, 
South 
Africa 
117 
patients 
on ART 
Improved HRQoL 
due to access to 
ART. Improvement 
was evident at the 
first month post 
ART initiation. 
Louwagie 
et al. 2007 
EQ-5D 
and VAS 
Cross- 
sectional 
study 
Baseline only Free State 
Province, 
South 
Africa 
268 
patients 
on ART 
and 103 
ART 
naïve 
patien
ts 
Improvements in 
HRQoL after 
initiation on ART 
as compared to the 
control group. 
Nglazi et 
al. 2014 
EQ-5D 
and VAS 
Cross- 
sectional 
study 
Baseline only Cape 
Town, 
South 
Africa 
435 
patients 
on ART 
and 468 
ART 
Naïve 
patient
s. 
HRQoL 
improved with 
ART use. 
Abera et 
al. 2010 
Short 
Form 36 
(SF-36) 
Cross- 
sectional 
study 
Baseline only Central 
and 
southern 
Ethiopia, 
Ethiopia 
422 
patients 
on ART 
for at 
least 
three 
months. 
Better HRQoL 
associated with 
high CD4 counts 
(above 
200cells/mm
3
), on 
ART for longer 
than 12 months, 
attained a 
secondary 
school 
education and 
employment. 
Friend-du WHOQ Cross- Baseline only KwaZulu- 618 More symptoms 
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Preez and 
Peltzer 
2010 
OL-HIV sectional 
study 
 Natal, 
South 
Africa 
initiating 
on ART. 
associated with low 
income and vice 
versa. Higher 
education level 
associated with better 
HRQoL. 
Peltzer 
2012 
WHOQ 
OL-HIV 
BREF 
Prospective 
cohort study 
Three 
measurement 
s at baseline, 
6 and 12 
months on 
ART 
KwaZulu
- Natal, 
South 
Africa 
735 
patients 
initiating 
on ART. 
Quality of life 
improved in patients 
on ART, as well as 
those that had income 
or receiving social 
grant and had 
employment. 
Mûnene 
and 
Ekman 
2014 
SF-36 Cross- 
sectional 
study 
Baseline only Kenya 392 
patients on 
ART. 
Higher education and 
employment were 
associated with better 
HRQoL. There was no 
association between 
baseline WHO clinical 
stage and HRQoL. 
Tesfay et 
al. 2015 
WHOQ 
OL-HIV 
BRIEF 
Comparative 
cross- 
sectional 
study 
Baseline only Northern 
Ethiopia 
253 males 
and 253 
females 
patients on 
ART 
Women scored lower 
than men. Low 
educational status, 
low monthly income 
and stigma were 
related to poor 
HRQoL. There was no 
difference in the 
perceived poor quality 
of life in both male 
and female 
participants when it 
came to educational 
status and income 
level. 
Igumbor 
et al. 2013 
WHOQ 
OL-HIV 
Comparative 
cross- 
sectional 
study 
Baseline only South 
Africa 
311 ART 
naïve 
patients 
and 331 
on ART 
for 12 
months. 
Patients on treatment 
for 12 months had 
better quality of life 
compared to treatment 
naïve patients. 
Stangl et 
al. 2012 
MOS- 
HIV 
Prospective 
cohort study 
Baseline only Tororo 
and Busia, 
Uganda 
947 adults 
initiating 
on ART 
Participants with no 
education, no income 
and low CD4 counts 
had a poor HRQoL. 
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Stangl et 
el. 2007 
MOS- 
HIV 
Cohort study Five 
measurement 
s at baseline, 
every three 
months up to 
12 months 
Uganda 710 HIV 
infected 
women 
and 
237 HIV 
infected 
men on 
ART 
Financial dependence, 
unemployment, CD4 
counts of less than 
50cells/mm³ and high 
viral loads >/5 log10 
copies/ml were 
associated with poor 
HRQoL at baseline. 
Once ART was 
initiated and CD4 cell 
count increased there 
was improvement in 
QoL most gains were 
achieved by the third 
month of ART 
therapy. 
Deribew 
et al. 2013 
WHOQ 
OL HIV- 
Brief 
Prospective 
cohort study 
Two 
measurement 
s at baseline 
and again at 6 
months 
Ethiopia 465 on 
ART and 
 
124 on 
ART and 
anti-TB 
treatment
. 
Improvement in 
quality of life was 
better in patients with 
HIV and TB co- 
infection. There was 
however no 
statistically significant 
relationship between 
quality of life and 
employment or 
income. 
Mwesigire 
et al. 2015 
MOS- 
HIV and 
Global 
Person 
Generate 
d Index 
(GPGI) 
Prospective 
cohort study 
Two 
measurement 
s were done 
at 3 months 
and then 
again at 6 
months 
Uganda 640 on 
ART and 
643 ART 
naive 
No relationship 
between CD4 cell 
count and quality of 
life. Low education 
was negatively 
associated with 
HRQoL. 
Abboud et 
al. 2010 
MQoL- 
HIV 
Cross- 
sectional 
descriptive 
study 
Baseline only Lebanon 41 on 
ART 
Education level up to 
elementary had 
significantly higher 
HRQoL compared to 
those with university 
qualifications. 
Ayodele et 
al. 2014 
WHOQ 
OL- 
BRIEF 
Cross- 
sectional 
study 
Baseline only Nigeria 491 on 
ART 
No gender differences 
in all domains of 
quality of life, no 
education or primary 
 
 
 
 
http://etd.uwc.ac.za
32  
      education reported 
better HRQoL. 
Rueda et 
al 2011 
MOS- 
HIV 
Cross 
sectional 
Study 
Baseline only Toronto, 
Canada 
361 on 
ART 
Employments was 
strongly associated 
with better QoL. 
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CHAPTER 3 
 
 
 
 
METHODOLOGY 
 
 
 
3.1 INTRODUCTION 
 
This study was descriptive and quantitative in design. The study design included both a cross 
sectional component which described the study population and divided the population into those 
participants eligible for ART and those not eligible for ART. A prospective cohort design followed 
the subset of participants eligible for ART and follow-up measurements were done on this group 
after two to three months on ART to compare changes. Two structured questionnaires were 
developed from validated data collections tools. 
3.2 RESEARCH SETTING 
 
The setting was an urban hospital and two surrounding clinics in Johannesburg. The study 
population included HIV-positive patients attending hospital A, primary health care clinic B and 
C in Johannesburg. Hospital A is in Gauteng Province, it is a large, urban public hospital with 
12000 patients on ART as of June 2015 at the time of data collection. Hospital A initiate on average 
60 patients on ART every month. The majority of patients who test HIV-positive at hospital A but 
are not yet eligible for initiation on ART because their CD4 counts are above 500cells/mm
3 
are 
down referred to clinics B and C. In addition, these two clinics test on average 50 patients per 
month for HIV and out of these an average of 10 patients test positive every month, according to 
data from the District Health Information System (DHIS). 
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This hospital was selected due to convenience of access and because hospital A has one of the 
largest clinics that offer ART services in Gauteng Province. The two clinics were selected because 
the study population would be similar to hospital A in terms of demographics. 
3.3 RESEARCH POPULATION AND SAMPLE 
 
Sample size was dependent on the resources, availability/ willingness of participants to be part of 
the study and a limited time framework. 
3.3.1 Research Population 
 
The study population comprised of the 12000 patients from the age of 18 years and older currently 
attending either hospital A, clinic B and/or C. The sample size was aimed at 60 patients that were 
initiated on ART on a monthly basis at hospital A and 60 patients not yet eligible for ART at clinics 
B and C. 
3.3.2 Research sample 
 
Convenience sampling was used to recruit patients into the study due to time constraints. This 
sampling method was dependent on participants‟ choice to participate in the study or not. A 
convenience sample of 120 patients was planned to be recruited into the study, of which 60 
participants was to be eligible to initiate on ART and 60 not yet eligible for ART. Patients that 
were excluded from the study were anyone HIV-negative, under the age of 18, pregnant and/or 
already on ART. Patients that were included in the study were HIV-positive ART naïve patients, 
or patients considered for initiating ART, who consented to be part of the study and adults above 
18 years of age. 
Participants at hospital A were recruited from the initiation room, this is a room where new patients 
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that are due to start treatment see a nurse who ensures patients have received counselling and are 
ready to start treatment. Informed consent was obtained.  The baseline questionnaires were 
administered by the investigator to those that gave written informed consent. Follow up 
questionnaires were then administered two to three months after initiation of therapy. 
Participants at clinics B and C were first identified through their clinical records and the results 
book, because there were no electronic clinical records of patients or booking/appointment 
systems. Patients who met the inclusion criteria were then phoned to determine their willingness 
to participate in the study. Once they agreed to be part of the study the date of their next clinic visit 
was noted. During their clinic visit they were recruited into the study and written informed consent 
was undertaken, together with the administration of the two questionnaires. This group of patients 
was not followed up due to time constraints. 
3.4 DATA COLLECTION 
 
3.4.1 Data collection instrument and characteristics 
 
In this study two structured questionnaires were used to collect data directly from participants and 
from participants’ medical records. Additional information such as baseline CD4 count and WHO 
stage were obtained from patients’ medical records.  Structured interviews were conducted in order 
to ensure that patients who cannot read or write were not excluded, as well as to standardize data 
collection to reduce interviewer error. 
The two structured questionnaires included a socio-economic questionnaire (Appendix 4) and a 
health related quality of life questionnaire (Appendix 3). The socio-economic questionnaire was 
extracted from questions of the General Household Survey 2013 conducted by Statistics South 
Africa (Statistic South Africa, 2014). This questionnaire was designed to collect demographic data 
(age and sex), socio-economic data (highest level of education, income and employment status) and 
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clinical data (CD4 count and WHO stage) (Table 3.1).  
The health related quality of life questionnaire that was used to collect the data included the EuroQol 
health questionnaires. The tool has two sections, namely the EQ-5D from which the EQ-5D-5L 
index score was calculated and the visual analogue scale (VAS) score (EQ-VAS).  The EQ-5D 
section is divided into five domains which include mobility, self-care, usual activities, pain or 
discomfort and anxiety or depression. Each domain has five levels which are: no problem, slight 
problem, moderate problem, severe problem and unable to perform. The value sets derived from 
the five domains of the EQ-5D can be used to deduce the overall health score for each patient, which 
is referred to as the index score (a full health score is equal to 1). The index score can be determined 
using the EQ-5D-5L crosswalk index value calculator version 2, which has value sets that are 
representative sample of the general population this is found on the EuroQol website (EuroQol 
Group, 2009). The second section is EQ-VAS which is a record of  the patient’s self-rated health 
status on a scale of 0 to 100.The participant does a selection on how they perceive their health on 
that particular day on the scale of 0 to 100, where 0 means the worst health and 100 means the best 
health one can imagine. 
The EQ-5D questionnaire was selected as it has already been authenticated in HIV/AIDS patients 
in South Africa by Jelsma et al. (2005). Hence the reliability and validity of this tool has been 
proven in South Africa (Jelsma et al., 2004). It was designed to be self-administered and short 
enough to be used in conjunction with other measures. It took about a minute to complete. It has 
been translated in many of the South African official languages including Sotho, Xhosa and Zulu 
(Jelsma et al., 2004).
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Table 3.1 Summary of variables included in data collection tools. 
 
 
Dependent variables Independent variables 
Quality of life indicators Socio-demographic 
characteristics 
Clinical characteristics 
Mobility, self-care, usual 
activities, pain/discomfort, 
depression/anxiety, index 
score, VAS score 
Age, gender, education 
status, income and 
employment status 
CD4 count, ART status and 
WHO stage 
 
 
 
3.5       ETHICAL CONSIDERATIONS 
 
Permission to conduct this study was granted from the University of the Western Cape Senate 
Research Ethics committee (ref 15/7/237), as well as institutional approval from the hospital CEO 
and Gauteng Province Department of Health district office for permission to conduct the study at 
two primary health care facilities. 
The principles of ethical research during data collection were respected at all times ensuring 
patients’ rights, dignity and confidentiality. The most important aspect of informed consent was to 
inform participants on why the study was being conducted, how it will impact on them as study 
participants and the importance of their consent (see Appendix 2) to being part of the study. This 
required cautious groundwork involving explanation and consultation as well as ensuring the 
participants understood everything before any data collection commenced. Every participant gave 
their written consent before they were enrolled in the study. If the participants requested that 
information and the consent form to be in their language, it was provided as such. 
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Participants were informed of their right to refuse to be part of the study, and could withdraw 
anytime. Patient information leaflets (Appendix 1) explaining the purpose of the study and how 
their data will be used were provided. 
Anonymity was maintained by assigning each study participant with a unique identifier (hospital 
number was used for follow-up purpose) on the consent form that was linked to the set of 
questionnaires. The consent forms were kept locked away in a different location from the 
questionnaires. The information and findings from this study were be used for academic purposes 
only. Handling of data was restricted to the research team as the CEO only allowed access to the 
people included in the research permission form. The statistician only had access to anonymous 
data. Participants were also requested to give consent for the research team to access their medical 
records, as well as anonymous data to be accessed by the statistician. 
Information that could identify individual patients was not used or disclosed for purposes other 
than healthcare. Storage, handling and sharing of data were most critical and therefore, a lockable 
cabinet was used to store hard copy data and the data stored on the computer was password 
protected. Data collected will be destroyed once research reports has been completed and 
examined. 
People living with HIV are considered vulnerable and therefore, the participants in this study were 
not coerced into the study. If they chose not to participate in the study they still received the same 
level of care. The hospital CEO assessed the risks versus the benefits the study posed to the patients 
before the study was approved. 
Participants were not put under any unnecessary risk during the study. The risks and benefits of 
participating in the study were clearly explained in the patient information leaflet (see Appendix 
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1). Over-burdening participants with long questionnaires was avoided and questionnaires were 
designed such that they do not take longer than half an hour to complete. 
3.6       DATA ANALYSIS  
 
Data from the questionnaires were captured onto an Excel spreadsheet. The socio-economic data 
were categorized as follows: highest level of education completed (grade 1-7, Grade 8-11, Grade 
12, >12), employment status (employed, self-employed or not employed), and income level 
(<R500, R550-R2000, R2500-R5000, >R5000).  
Clinical characteristics analysed included: WHO stage (stage 1, 2, 3, 4), CD4 count (cell/mm³) 
(≤200, 201-350, 351-500, >500). Each domain of the HRQoL questionnaire was captured 
according to the five different levels in the questionnaire. From the scores of the aforementioned 
five domains, the index score of each patient was determined using EQ-5D-5L crosswalk index 
value calculator version 2 found on the EuroQol website. The VAS score was captured. The data 
were double checked for errors before the spreadsheet was imported into STATA. 
Statistical analysis was done using STATA version 14. Descriptive statistics was used to 
summarise baseline characteristics. Central tendency of the continuous variables were analyzed 
using mean and standard deviation if their distribution was normal and using the median and 
interquartile range if their distribution was not normally distributed (Figure 1). Categorical 
variables were described using frequencies and percentages using tabulations. The baseline 
characteristics of all the study participants in terms of demographics, socio-economics, clinical 
indicators and HRQoL will be presented using the aforementioned descriptive statistics.
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The baseline data were separated by ART eligibility status of participants to infer any differences 
between the group eligible and not eligible to start ART. The paired t-test will be used for normally 
distributed variables, and non-parametric tests (Mann-Whitney test or Kruskal-Wallis) for non-
normally distributed variables to test for association between exposures and outcomes. For 
categorical variables the Chi-squared (χ2) test was used provided the conditions for using this test 
was met (e.g. number of observations per cell is more than 10), if not the Fischer’s exact test was 
used.   The level of significance was set at P<0.05.   The HRQoL indicators will be further tabulated 
and dichotomised into baseline and two to three months follow up for those starting ART. 
Poison regression analysis with robust standard errors will be used to estimate the relative risk and 
the 95% confidence interval of an unfavorable outcome (in this case the problem sub- category) 
while controlling for possible confounders. A univariate analysis to test association between the 
outcome and each variable (socio-demographic/clinical variables) individually was done. Then 
from this, significant association by checking the p value was determined. At this stage there was 
more leniency so the cut-off is set at p <0.200.  All factors with a p value equal or less than 0.200 
were considered for the multivariate analysis. Some factors were not significant in the univariate 
analysis (i.e. ART status) but were forced in the multivariate analysis because it is known from 
previous studies and literature review done that they influenced the outcome. Therefore, factors 
known to be of importance were included irrespective of significance in the univariate analysis. 
The HRQoL outcomes under self-care in the ‘problem’ category none of the groups reported any 
problems therefore this was not included in the regression analysis. WHO staging was also left out 
because only 23% of the patients had their WHO documented in the file. 
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CHAPTER 4 
 
 
 
RESULTS AND DISCUSSION 
 
 
4.1 RESULTS 
 
A total of 106 participants were recruited and enrolled in the study. Forty-six participants were 
recruited from the two clinics and were not eligible for ART, and, 60 participants were recruited 
from the hospital site and eligible to be started on ART. Of the 60 participants who started ART, 
one participant was lost to follow-up at the two to three month follow-up period. 
 
Figure 1. The distribution of continuous variables; age, CD4 cell count, income (income 1 is 
baseline income and income 2 is 2-3 months income), index score (index score 1 and 2 are baseline 
and 2-3 months index scores respectively) and VAS score (VAS score 1 and 2 are baseline and 2-
3 months follow up scores respectively). Only age was normally distributed, while others were 
either skewed to the right or to the left. 
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4.1.1 Participant characteristics 
 
The sociodemographic and clinical characteristics of the 106 participants enrolled at baseline are 
presented in Table 4.1. There were 103 black participants, 2 white and 1 coloured. The baseline 
group had a median age of 36 IQR (30-44) years and about 70% were female. Almost half of the 
participants had an education level of Grade 12 (41.57%) and higher (8.49%).  About 67% of 
participants were either employed or self-employed. Half of the participants had a CD4 count of 
more than 500cells/mm
3
. In terms of income, the main source of income was salary (56.60%) the 
median income was R1500 (IQR R0-R3800). Only 15 participants had recorded WHO stage in their 
clinic records and of these 60% were stage 1. The WHO stage was thus not further analysed or 
reported on. 
The baseline group was further divided into those 46 participants not eligible for ART and those 60 
who were eligible for ART.  Participants eligible for ART were significantly older than those not 
eligible for ART with a median of 38 (IQR 32-46) years and median of 34 (IQR 27-43) years, 
respectively (p=0.008). The group not yet eligible for ART comprised of mostly women (91.30%) 
versus the ART eligible group that comprised only about half of women (53.33%) (p< 0.001). Both 
groups had comparable levels of education, employment status and income, however income 
increased post ART initiation (p=0.013) (see appendix 5 table 4.5). As expected the group not yet 
eligible for ART had a significantly higher CD4 count compared to the ART group with median of 
697.50 (IQR 589-900) and 213.50 (IQR 80-387.50), respectively, (p < 0.001) (Table 4.1).
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Table 4.1 Demographic, socio-economic and clinical characteristics of the study population 
 
 
Demographic, socio-economic and clinical characteristics of the 106 participants in the study 
population. This population was divided into the group of 46 participants not yet eligible for ART 
(ART naïve) and 60 participants eligible to start ART (ART). 
 Total ART-naïve ART  
p-value (n= 106) (n= 46) (n= 60) 
n (%) n (%) n (%) 
Age, yrs., median (IQR) 36 (30-44) 34(27-43) 38 (32-46) 0.0084 
Gender     
<0.001 Female 74 (69.81) 42 (91.30) 32 (53.33) 
Males 32 (30.19) 4 (8.70) 28 (46.67) 
     
Education     
 
 
0.492 
No education 2 (1.89) 0 (0.00) 2 (3.33) 
Grade 1-7 18 (16.98) 13 (28.26) 5 (8.33) 
Grade 8-11 33 (31.13) 10 (21.74) 23 (38.33 
Grade 12 44 (41.51) 18 (39.13) 26 (86.67) 
>Grade 12 9 (8.49) 5 (10.87) 4 (6.67) 
     
Employment     
0.207 
Employed 64 (60.38) 25 (54.35) 39 (65.00) 
Self employed 7 (6.60) 4 (8.70) 3(5.00) 
Unemployed 35 (33.02) 17 (36.96) 18 (30.00) 
     
Income, median (IQR) 1500 (0-3800) 1650 (0-4500) 2218 (0-2218)  
≤R500 4 (5.63) 2 (6.90) 1 (2.38)  
 
0.896 
R550-R2000 18 (25.35) 6 (20.70) 13(30.95) 
R2500-R5000 23 (32.39) 12 (41.38) 11 (26.19) 
>R5000 6 (8.45) 5 (17.24) 1 (2.38) 
Did not want to disclose 20 (28.17) 4 (13.79) 16 (38.10) 
     
CD4 count, cell/mm³ median (IQR) 494.50 (155-680) 697.50 (589-900) 213.50 (80-387.50) <0.001 
≤200 29 (27.36) 0 (0.00) 29 (48.33)  
<0.001 
>201 - 350 12 (11.32) 0 (0.00) 12 (20.00) 
>351 - 500 12 (11.32) 0 (0.00) 12 (20.00) 
>500 53 (50.00) 46 (100.00) 7 (11.67) 
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4.1.2 Comparison of health related quality of life outcome by ART status at baseline and 
two to three months post ART initiation 
Table 4.2 summarises the HRQoL measurements of both the cross-sectional and the cohort results 
of all the participant groups. The HRQoL for the entire baseline group was most affected by pain 
and discomfort, followed by depression and anxiety, amounting to 40.57% and 23.58% of 
participants, respectively. The only significant difference between the ART and non-ART groups 
were that the ART group initially experienced more problems with usual activities (18.33%) than 
the non-ART group (2.00%), (p = 0.037). However, the VAS score indicated that at baseline ART 
group had a significantly higher median of 90 (IQR 76.50-99) while non-ART group scored 
median 66.50 (IQR 60-80); (p < 0.001). A sub-analysis within the ART and ART naïve groups to 
see if there were any significant differences in the VAS between genders for the entire group (ART 
& ART naive, and within each ART status group) was done. The results for each analysis indicated 
that there was no statistically significant difference in the baseline VAS score mean for males and 
females for all study participants (p = 0.315). There was also no difference in the baseline VAS 
score median for males and females among the ART participants (p = 0.487), and no difference in 
the ART naïve participants (p = 0.678) (see appendix 5 Table 4.4). 
At two to three months follow up of the group that started ART, there was one patient that was 
lost to follow up. The total number of ART group changed from 60 to 59. The HRQoL for ART 
group at two to three month follow up improved significantly except for usual activities.  Mobility 
improved from 86.67% to 98.31% (p = 0.011), pain/discomfort increased from 60% to 83% (p = 
0.005), depression/anxiety rose from 78% to 84% (p = 0.008).  Median VAS score increased 
from 90 to 98 (p < 0.001). 
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Table 4.2 Health-related quality of life (EuroQol) of ART-naïve and ART groups at study baseline and ART baseline vs ART 2- 
3 months after study enrolment 
Analysis using Pearson's chi-square (χ2), Fischer's exact test for number of observations per cell of less than 5, as well as t-test 
for continuous variables were undertaken. 
 Baseline 2-3 months follow-up 
  
Total 
ART-naïve 
(study 
baseline) 
ART 
(study  baseline) 
 
 
P value 
ART 
(study 
baseline) 
ART 
(2-3 months 
follow-up) 
 
 
P value 
 n=106 n=46 n=60 n=60 n=59 
 N (%) N% N% N% N% 
Mobility        
No problems 92 (86.79) 40 (86.96) 52 (86.67) 
0.965 
52 (86.67) 58 (98.31) 
1 (1.69) 0.011 Problems 14 (13.21) 6 (13.04) 8 (13.33) 8 (13.33) 
        
Self-Care        
No problem 103 (97.17) 46 (100) 57 (95.00) 
0.256 
57 (95.00) 59 (100.00)  
N/A Problems 3 (2.83) 0 (0.00) 3 (5.00) 3 (5.00) 0 (0.00) 
        
Usual Activities        
No problems 93 (87.74) 44 (95.65) 49 (81.67) 
0.037 
49 (81.67) 56 (94.92)  
0.086 Problems 13 (12.26) 2 (2.00) 11 (18.33) 11 (18.33) 3 (5.08) 
        
Pain/Discomfort        
No problems 63 (59.43) 27 (58.70) 36 (60.00) 
0.892 
36 (60.00) 49 (83.05)  
0.005 Problems 43 (40.57) 19 (41.30) 24 (40.00) 24 (40.00) 10 (16.95) 
        
Depression/Anxiety        
No problems 81 (76.42) 34 (73.91) 47 (78.33) 
0.595 
47 (78.33) 50 (84.75)  
0.008 Problems 25 (23.58) 12 (26.09) 13 (21.67) 13 (21.67) 9 (12.25) 
        
Index Score (IQR) 0.88  (0.81-0.90) 0.86  (0.81-0.90) 0.90 (.81-.90) 0.705 0.90 (.81-.90) 0.90  (0.86-0.90) 0.0001 
VAS score, median (IQR) 80 (65-93) 66.50 (60-80) 90  (76.50-99.00) <0.001 90 (76.50-99.00 98 (90.00- 100.00) <0.001 
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4.1.3 Comparison of health related quality of life outcomes with sociodemographic and 
clinical outcomes 
Table 4.3 shows the baseline group’s univariate and multivariate analyses of certain variables such 
as age, gender, education level, employment status, ART status, CD4 count, index scores and VAS 
scores as associated with the five domains in the HRQoL questionnaire. The univariate analysis 
shows that males were 9% (CI 0.86-0.97) (p=0.004) less likely to experience significant problems 
with mobility than females. With higher education thus above grade twelve the percentage change 
in the incident rate of not experiencing problems with mobility is an increase of 75% (CI 1.02-
1.13) (p=0.005) for every unit increase in education. This means that patients with higher education 
have less problems with mobility.  Self-employed participants were 9% (CI 0.89-1.00) (p=0.034) 
less likely to experience problems with usual activities. The participants not yet eligible for ART 
(ART naïve group) was 11% (CI 1.01-1.20) (p=0.025) less likely to experience problems with 
mobility and 21% (CI 1.06-1.38) (p=0.004) less likely to experience problems with 
pain/discomfort than the group of participants eligible for ART (ART group). Participants with 
CD4 counts above 500 cell/mm³ were 11% (CI 1.03-1.20) (p=0.006) less likely to experience 
problems with mobility than participants with lower CD4 counts. 
The multivariate analysis did not find a difference in the HRQoL outcomes in mobility and usual 
activities. There was nevertheless an 11% (CI 0.76-0.93) (p=0.001) less likelihood that ART naïve 
group would experience problems with anxiety/depression than the group eligible for ART. 
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Table 4.3 univariate and Multivariate analyses showing factors associated with the five Health related Quality of Life (EuroQol) domains 
 
Univariate analysis indicated no difference in HRQoL in all domains of HRQoL. 
 
The multivariate analysis indicate that ART naïve group is less likely to experience problems with pain/discomfort and Anxiety/depression 
Variable 
Mobility Usual activities Pain/discomfort Anxiety/depression 
IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value 
Age 1.00 (.99-1.00) 0.668 0.99 (0.99-1.00) 0.159 1.00 (1.00-1.00) 0.763   1.01 (1.00-1.01) 0.064 1.00 (1.00-1.01) 0.29 1.00 (1.00-1.01 0.356 1.00 (0.99-1.00) 0.899 
Gender                 
Female 1.00 (1.00-1.00)                
Males 0.91 (0.86-0.97) 0.004 0.98 (0.93-1.03) 0.356 1.02 (0.93-1.12) 0.629 1.03 (0.93-1.15) 0.592 0.88 (0.76-1.10) 0.062 0.97 (0.89-1.07) 0.576 1.00 (0.86-1.16) 0.987 1.08 (0.96-1.21) 0.217 
                 
Education                 
No education 1 (1-1) 0.988               
>Grade 12 1.75  (1.02-1.129) 0.005 1.05 (0.95-1.17) 0.338 0.94 (0.78-1.13) 0.511 0.92 (0.78-1.08) 0.301 1.04 (0.83-1.32) 0.716 1.01 (0.91-1.11) 0.88 1.1 (0.90-1.34) 0.902 1.04 (0.85-1.27) 0.69 
≤Grade 12 1 (1-1) 0.988 1.03 (0.86-1.23) 0.771 0.90 (0.75-1.05 0.266 0.83 (0.68-1.02) 0.723 1.23 (.73-2.05) 0.436 1.12 (.82-1.54) 0.471 0.9 (0.75-1.08) 0.266 0.97(0.76-1.25) 0.836 
                 
Employment                 
Employed 1 (1-1)                
Self employed 0.96 (0.91-1.00) 0.071 0.98 (0.89-1.08) 0.649 0.94 (089.1.00) 0.034 0.95 (0.86-1.05) 0.303 1.02 (0.77-1.34) 0.911 1.07 (0.87-1.32) 0.521 1.04 (0.79-1.36) 0.805 1.04 (0.85-1.28) 0.677 
Unemployed 1.07 (0.96-1.19) 0.241 1.08 (0.98-1.18) 0.122 0.97 (.90-1.05) 0.432 0.99 (0.91-1.08) 0.767 1.02 (0.88-1.18) 0.766 1.04 (0.93-1.17) 0.446 0.91 (0.79-1.04) 0.148 0.91 (0.82-1.01) 0.787 
                 
ART status                 
ART 1 (1-1)                
ART-naïve 1.11 (1.01-1.22) 0.025 1.08 (0.96-1.22) 0.183 0.99 (0.92-1.07) 0.86 1.01 (0.96-1.07) 0.665 1.21 (1.06-1.38) 0.004 1.10 (0.99-1.21) 0.655 1.08 (0.95-1.24) 0.233 0.84 (0.76-0.93) 0.001 
                 
CD4 count                 
≤200 1 (1-1) 0.999               
>201 - 350 1 (1-1) 0.999 1.07 (0.97-1.17) 0.169 0.91 (0.82-1.00) 0.056 0.91 (0.81-1.02) 0.101 0.85 (0.70-1.03) 0.976 0.90 (0.79-1.03) 0.12 1.01 (0.81-1.26) 0.921 1.01 (0.85-1.18) 0.949 
>351 - 500 1.09 (0.93-1.26) 0.276 1.14 (0.99-1.32) 0.07 0.91 (0.82-1.00) 0.056 0.91 (0.79-1.050 0.188 0.86 (0.70-1.05) 0.129 0.86 (0.72-1.04) 0.115 1.10 (0.87-1.40) 0.424 1.05 (0.86-1.28) 0.647 
>500 1.11 (1.03-1.20) 0.006 1.13 (0.95-1.35) 0.18 0.94 (0.84-1.05 0.285 0.94 (0.79-1.11) 0.438 1.06 (0.91-1.25) 0.441 0.85 (0.67-1.09) 0.212 1.07 (0.92-1.24) 0.408 0.89 (0.72-1.10) 0.289 
                 
IRR - Univariate Incident Rate Ratio                
aIRR- Multivariate Incident Rate Ratio               
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4.2 DISCUSSION 
 
The cross-sectional study looked at HRQoL between the two groups of patients, those that were 
eligible for ART and those not yet eligible for ART. The group not yet eligible for ART comprised 
of mostly women (91.30%) versus the ART group that comprised only about half of women 
(53.33%) P<0.001. This could be similar to the finding of the study conducted by Louwagie et al. 
(2007) that most women seek health care services early while their CD4 cell counts are still high 
and therefore will be in the pre ART services at health care facilities before they can initiate ART. 
Men usually wait until they are sick to seek medical attention and hence their CD4 cell count would 
be low. 
In terms of HRQoL, the main findings were as follows: firstly, the ART eligible group had 
significantly more problems in the domain of usual activities as compared to the group not yet 
eligible (p = 0.037), yet the overall index scores (that take into account all five domains) showed 
no significant difference between the two groups, and, secondly, the VAS scores were significantly 
higher in the ART eligible group (p < 0.001). The VAS score is an indication of how a participant 
perceives his or her overall health on that particular day and the value of this measurement may be 
limited by the absence of information about any acute conditions experienced by participants on 
the day of data collection. The WHO stage would assist with providing an indication of symptoms 
the patient maybe experiencing that could potentially affect their perceived health. These data were 
missing in the majority of clinical stationary. Looking further into the difference between the 
groups, the fact that the group not yet eligible for ART was significantly younger than the ART 
eligible group (p = 0.0084) may have influenced the younger group to have higher expectations of 
their health. An analysis within the ART group to see if there were any significant differences in 
the VAS score between genders was conducted. 
49 
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There was no difference in the baseline VAS score mean for males and females among the ART 
participants (p=0.487) and thus gender was eliminated as the cause of this difference. Ayodele et 
al. (2014) also found no gender difference in all domains of HRQoL in their study, on the other 
hand Tesfay et al. (2015) and Abasiubong et al. (2010) both found that female gender experienced 
lower HRQoL as compared to men. Lastly, it is interesting to note that although the CD4 counts 
of the group not yet eligible for ART were significantly higher than the ART eligible group, it still 
did not translate to a perception of better health as per the VAS score. 
The HRQoL outcomes improved significantly upon access to ART treatment, this was evident in 
the two to three months follow up data. The ART group at two to three months compared to their 
baseline measurements had a significantly higher index score (p = 0.0001) and VAS score (p < 
0.001). Index score of 1 is the value for full health therefore, our ART patients were very close to 
1 at 0.90.  Regarding the VAS score, 100% is the best imaginable health and ART patients scored 
98%. The results could be generalized to the study population because the index score is based on 
the values of the general population as opposed to the VAS score which is based on the patients 
‘self-perception of their health, but because the sampling technique used was not random and the 
sample size was not representative of the study population caution should be exercised when 
making generalisations. 
Similar results were reported by Stangl et al. (2007), who determined that once ART was initiated 
and CD4 cell count increased there was improvement in QoL, they further indicated that most 
gains were achieved by the third month of ART therapy. In addition, Jelsma et al. (2005) found 
that patients with HIV in resource poor countries can have improved quality of life due to access 
to antiretroviral (ARV) treatment. Improvement was evident in all domains of the EQ- 5D, which 
was already evident in the first month post ART initiation.   Abera et al. (2010)
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established that patients with high CD4 counts (above 200cells/mm³), on treatment longer than 12 
months were associated with better HRQoL. Igumbor et al. (2013) concluded that patients on 
treatment for 12 months had better QoL compared to treatment naïve patients. 
The following studies conducted by Louwagie et al. (2007), Nglazi et al. (2014) and Peltzer (2012) 
found similar results: Louwagie et al. (2007) showed improvements in QoL after initiation on ART 
as compared to the control group, improvements were seen in all five domains of the EQ-5D, even 
though the results are similar the studies are not directly comparable due to different sample size. 
Nglazi et al. (2014) found that HRQoL was improved with ART use and that ART patients had 
higher VAS scores compared to ART naïve group. Peltzer (2012) determined that QoL improved 
in patients on ART and besides a good study sample of 735 participants the follow up was longer 
at baseline, 3 months, 6 months and 12 months. 
Employed and self-employed participants were less likely to report problems in the univariate and 
multivariate analysis compared to unemployed participants signifying better HRQoL.  Further 
analysis into income (see appendix 5 table 4.5) indicated that post ART therapy the median income 
changed from R2218.30 to R2464.87 (p=0.013). The participants with higher education above 
grade 12 were less likely to report problems in the univariate and multivariate analysis compared 
to participants with education below grade 12 indicating better HRQoL. This was reported in other 
studies by Friend-du Preez and Peltzer (2010), Peltzer (2012), Mûnene and Ekman (2014) and 
Tesfay et al. (2015) they indicated that employment and higher education were associated with 
better HRQoL. Deribew et al. (2013) did not however find any relationship between HRQoL and 
employment or income. 
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Notwithstanding that the ART naïve group in this study was not followed up, it should not skew 
the results drastically because there was no intervention done on this group and for that reason one 
would expect not to see any change in this group’s outcomes. 
The strengths of the study were the use of the index score in combination with the VAS score to 
determine the HRQoL. There was only one patient lost to follow up. There was limited bias when 
administering questionnaires because they were not self-administered rather they were 
administered by someone who could translate the questionnaire to participants who could not 
understand English. 
4.2.1 Limitations of the study 
 
There were several limitations to the study. Firstly, sample size was not representative of the study 
population and only managed to recruit 46 ART naïve patients instead of 60, therefore care should 
be taken when generalizing the results to the study population. External validity of data will also be 
compromised as the sample size is not an accurate representation of the population. If random 
sampling was used this issue would be avoided. Secondly, the follow up period was too short and 
some patients were followed up at two months and others at three months, even though change in 
HRQoL was significant clinically, statistically it can still be questionable. Third, participants not 
yet eligible for ART at baseline were not followed up because their data were only collected towards 
the end of the data collection period. The reason being permission to collect data for these patients 
took too long and in order to meet the deadlines follow up could not be done. This is expected to 
be another limitation of the study as it will skew the data.  Fourth, Only 19 patients out of 60 of the 
ART group had CD4 counts in the range >350-500 cell/mm³ and >500 cell/mm³. This is an 
indication that despite changes in the South African HIV treatment guidelines patients still starts 
treatment at very low CD4 counts. As a result, we cannot come to a conclusion of the effect of ART 
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on QoL of patients with higher CD4 counts.  Fifth, other studies like Harding et al. (2014), Deribew 
et al. (2013) and Mûnene et al. (2014) indicated the issue of missing clinical data such as WHO 
stage in patients ‘clinical records this was also a substantial problem in this study. Only 15 out of 
106 participants had their WHO stage recorded in their medical records. Therefore, effect of WHO 
stage on HRQoL could not be analysed in this study hence the inability to further interrogate the 
VAS score due to lack of acute symptom data. Sixth, the study site was initially hospital A only, 
but during data collection it was discovered that patients not yet eligible for treatment with high 
CD4 counts were referred out to near-by primary health care clinics. Two clinics close to hospital 
A were selected. These amendments had to be authorized by the ethics committee as well as 
different levels within the health district. The approval took two months, which then influenced the 
follow up of some patients to two months instead of three months in order to meet the thesis 
submission deadline.
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CHAPTER 5 
 
 
 
CONCLUSIONS AND/ RECOMMENDATIONS 
 
 
5.1 CONCLUSIONS 
 
The purpose of this study was to investigate the health related quality of life of HIV-positive 
patients either eligible or not yet eligible for ART at a CD4 count cut off of 500cells/mm
3
. It also 
measured the HRQoL of the group that were initiated on ART two to three month post ART 
initiation. Finally, the influence of education level, employment status and income were also 
associated with HRQoL in these groups. 
There were conflicting findings for HRQoL between participants eligible for ART and the group 
not yet eligible for ART. The index score (i.e. the objective measure for HRQoL) did not indicate 
any significant difference between the two groups. However according to the VAS score (i.e. 
subjective HRQoL measure) there was a significant difference, showing the ART group having a 
significantly better HRQoL than the group not yet eligible for ART. Consequently, we will fail to 
reject or accept research hypothesis 1, because there was no conclusive difference between the two 
groups. 
It was found that access to ART treatment does bring about improvement in HRQoL, as measured 
by the EQ-5D questionnaire’s index score and the VAS score Improvements in HRQoL were 
significant two to three months post ART initiation. Therefore, we reject the null hypothesis H0 2 
because access to ART did show significant improvement in HRQoL two to three months post 
ART initiation. 
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Higher education level and employment as well as income were associated with better 
HRQoL. However conclusions on the effect of ART on HRQoL among patients with high 
CD4 counts could not be reached.  Therefore, we did not reject or accept research hypothesis 
three (3). 
5.2 RECOMMENDATIONS 
 
Further studies should be done to look at the impact of ART on HRQoL for patients with higher 
CD4 counts over an extended period than this study, especially with the implementation of 
universal test and treat in South Africa. More needs to be done to ensure that patients test early 
and hence access to ART treatment earlier. There is a need to ensure that primary health care 
facilities develop appointment and booking systems for patients which was a huge challenge faced 
during data collection. The documentation of WHO stage in the clinical stationary should be 
strengthened as well. 
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Appendices 
 
Appendix 1: Patient information leaflet 
 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of 
Pharmacy, University of the Western Cape, Robert 
Sobukwe Road, Bellville, 7535 
Tel: 021 9592864 
Ms. Mpato Mokobori 
Tel: 011 2768850 
Cell: 0736193324 
 
Patient Information Leaflet 
 
Protocol Title: 
 
 
Principal Investigator’s Name: Mpato Mokobori   
 
Principal Investigator’s Title: District Pharmacist   
 
Telephone No. of Principal Investigator:   0112768850   
 
You are being invited to take part in a clinical research study carried out at Themba Lethu Clinic. 
Before you decide whether or not you wish to take part, you should read the information 
provided below carefully and if you wish to discuss it with your family, friends or GP.  Take 
time to ask questions – do not feel rushed or under any obligation to make a hasty judgement. 
You should clearly understand the risks and benefits of participating in this study so that you can 
make a decision that is right for you – this process is known as Informed Consent. 
 
You are not obliged to take part in this study and if you decide not to participate it will have no 
effect on your future care. 
 
You may change your mind at any time (before the start of the study or even after you have 
commenced the study) for whatever reason without having to justify your decision and without 
any negative impact on the care you will receive from the medical staff. 
Analysis on Access to Antiretroviral therapy for patients with different income 
and educational level, and the effect of treatment on quality of life after three 
months of therapy. 
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WHY IS THIS STUDY BEING DONE? 
 
This study is being done because we want to learn how access to antiretroviral therapy will 
affect the quality of life and how soon after initiation of therapy within three months is the 
impact seen. 
 
WHO IS ORGANISING AND FUNDING THIS STUDY? 
 
This study is purely for research purpose and not routine care, it is conducted as part of a 
Master’s program and there will be academic qualification as well as career advancement for the 
researcher. 
 
HOW WILL IT BE CARRIED OUT? 
 
A study to look at the effect of treatment on quality of life will be undertaken at Themba Lethu 
clinic in Johannesburg South Africa. This will commence in November 2015 to June 2016. The 
study will be undertaken to look at estimating whether there are significant differences between 
two different groups of patients. Sample one will be participants that are being initiated on anti- 
retroviral treatment and sample two will be participants that have not yet been initiated on 
treatment. 
 
Participants will be asked a number of questions on two different occasions when they attend the 
clinic. You as the participants will be expected to be in the study for a period of three to four 
months. There will be a total of 120 patients in the study.  The sort of questions that will be 
asked include: what is your level of education?  What is your monthly income? Then there will 
be questions of quality of life such as mobility, self-care, usual activities, pain/discomfort and 
anxiety/Depression. These questionnaires will not take more than half an hour. So about one 
hour of your time will be required including time for informed consent. 
 
Some of the questionnaires may be sensitive and can offend or upset you. It has been indicated 
in the questionnaire why these questions are critical in the study and each patient needs to 
understand why they are being asked.  You can choose not to answer these questions. 
 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
 
You need to know what the study is about and that there will be no pain at all except a little 
inconvenience due to the questionnaires and informed consent that will be undertaken. There 
will be no additional care with study. All the questionnaires will be administered during normal 
clinic visits therefore there are no additional visits involved. There will be no compensation 
given for participation. 
 
BENEFITS: 
 
There is no direct benefit for your participation but there could be benefit for the overall clinical 
management of patients in future. 
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RISKS: 
 
Some of the questionnaires may be sensitive and can offend or upset you. It has been indicated 
in the questionnaire why these questions are critical in the study and each patient needs to 
understand why they are being asked.  You can choose not to answer these questions. 
 
You will also be inconvenienced as you will spend more time in the clinic for informed consent 
and questionnaires but the questionnaires have been designed such that they do not take longer 
than half an hour. 
 
Potential breach of patient confidentiality is a risk. Efforts will be made to keep personal 
information confidential. There will be no disclosure of your information to any third party 
unless it is made unidentifiable. 
 
WHAT IF SOMETHING GOES WRONG AS A RESULT OF MY PARTICIPATION IN THIS 
STUDY? 
 
This is a very low risk study and therefore no untoward effects are expected. The safety of 
participants will always be the first priority. 
 
WILL THERE BE ANY ADDITIONAL COSTS INVOLVED? 
 
There will be no additional cost involved as recruitment and follow up will be during your 
routine clinic visit and therefore not out of pocket expenses will be expected. 
 
CONFIDENTIALITY ISSUES 
 
Efforts will be made to keep personal information confidential. Your confidentiality will be 
maintained throughout the study. There will be no disclosure of your information to any third 
party unless it is unidentifiable. Your information will be accessed by me as the researcher and 
the statistician. 
 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the Research Ethics Committee. 
 
If results are published, may lead to cohort identification but not individual identification. 
 
Your information that has been collected will be stored in a locked cupboard and information 
collected on the Personal Computer will be password protected. The information and findings 
for this study will be used for academic purposes only. Data will be retained for not longer than 
the time needed for publication, it will be retained at our research site and it will be anonymous 
data only that will be stored. These data will be destroyed once the thesis has been completed 
and if publication is to be done then it will be destroyed once published. 
 
Access to your medical records will be sought from the hospital CEO and this records will be 
treated with confidentiality.  You will also give informed consent for the research team to have 
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access to your medical records. The data will be deleted from my computer and the research site 
where it will be stored. 
 
IF YOU REQUIRE FURTHER INFORMATION 
 
If you have any further questions about the study, or if you wish to withdraw from the study you 
may do so without justifying your decision and your future treatment will not be affected. 
 
For additional information now or any future time please contact: 
 
Name: Mpato Mokobori 
 
Address: Themba Lethu clinic –Helen Joseph Hospital, Perth Road, Westdene. 
 
Phone No: 0112768850 
 
Alternatively you can contact: 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of Pharmacy, University of the Western Cape, 
Robert Sobukwe Road, Bellville, 7535 
Tel: 021 9592864 
 
The committees giving ethical approval for this study is the UWC Faculty board Research and 
Ethics Committee and the UWC Senate Research Committee. If you have any problems or 
questions about this study you can also contact the Ethics committee directly at telephone 
number 021 9593170. 
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Appendix 2: Consent form 
 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of 
Pharmacy, University of the Western Cape, Robert 
Sobukwe Road, Belville, 7535 
Tel: 021 9592864 
Ms. Mpato Mokobori 
Tel: 011 2768850 
Cell: 0736193324 
 
CONSENT FORM 
 
Protocol Title: 
 
 
Please tick the appropriate answer. 
I confirm that I have read and understood the Patient Information Leaflet dated 
_24/04/2015 attached, and that I have had ample opportunity to ask questions all of which have 
been satisfactorily answered. Yes   No 
 
I understand that my participation in this study is entirely voluntary and that I may withdraw at 
any time, without giving reason, and without this decision affecting my future treatment or 
medical care. Yes   No 
 
I understand that my records may be viewed by individuals with delegated authority from 
  Hospital CEO DR. Bila_ Yes   No 
 
I understand that my identity will remain confidential at all times. Yes   No 
 
I am aware of the potential risks of this research study. Yes No 
 
I have been given a copy of the Patient Information Leaflet and this Consent form for my 
records. Yes   No 
FUTURE USE OF ANONYMOUS DATA: 
Analysis on Access to Antiretroviral therapy for patients with different income and 
educational level, and the effect of treatment on quality of life after three months of therapy. 
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I agree that I will not restrict the use to which the results of this study may be put. I give my 
approval that unidentifiable data concerning my person may be stored or electronically processed 
for the purpose of scientific research and may be used in related or other studies in the future. 
(This would be subject to approval by an independent body, which safeguards the welfare and 
rights of people in biomedical research studies) Yes   No 
 
Participant    
Signature and dated  Name in block capitals 
 
To be completed by the Investigator or his nominee. 
 
I the undersigned, have taken the time to fully explain to the above patient the nature and 
purpose of this study in a manner that he/she could understand. I have explained the risks 
involved, the experimental nature of the treatment, as well as the possible benefits and have 
invited him/her to ask questions on any aspect of the study that concerned them. 
 
 
 
Signature:   Name in Block Capitals: Qualification:   Date: 
 
 
 
Unique identifier 
 
3 copies to be made: 1 for patient, 1 for PI and 1 for hospital records. 
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Appendix 3: EQ-5D-5L Quality of life questionnaire 
 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of 
Pharmacy, University of the Western Cape, Robert 
Sobukwe Road, Bellville, 7535 
Tel: 021 9592864 
Ms. Mpato Mokobori 
Tel: 011 2768850 
Cell: 0736193324 
 
Unique ID 
 
 
Name of interviewer 
 
 
Date of interview 
 
 
Time interview started 
 
 
Time interview stopped 
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MOBILITY 
I have no problems in walking about 
I have slight problems in walking about 
I have moderate problems in walking about 
I have severe problems in walking about 
I am unable to walk about 
 
SELF-CARE 
I have no problems washing or dressing myself 
I have slight problems washing or dressing myself  
I have moderate problems washing or dressing myself  
I have severe problems washing or dressing myself 
I am unable to wash or dress myself 
USUAL ACTIVITIES (E.g. work, study, housework, family or 
Leisure activities) 
I have no problems doing my usual activities 
I have slight problems doing my usual activities 
I have moderate problems doing my usual activities 
I have severe problems doing my usual activities 
I am unable to do my usual activities 
PAIN / DISCOMFORT 
I have no pain or discomfort 
I have slight pain or discomfort 
I have moderate pain or discomfort 
I have severe pain or discomfort 
I have extreme pain or discomfort 
ANXIETY / DEPRESSION 
I am not anxious or depressed 
I am slightly anxious or depressed 
I am moderately anxious or depressed 
I am severely anxious or depressed 
I am extremely anxious or depressed 
71 




2 
Under each heading, please tick the ONE box that best describes your health TODAY. 





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Appendix 4: Socio-demographic questionnaire 
 
 
 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of 
Pharmacy, University of the Western Cape, Robert 
Sobukwe Road, Bellville, 7535 
Tel: 021 9592864 
Ms. Mpato Mokobori 
Tel: 011 2768850 
Cell: 0736193324 
 
 
 
 
 
SOCIO-DERMOGRAPHIC QUESTIONNAIRE 
 
 
 
 
 
 
 
Name of the interviewer: 
 
 
 
Date of interview: 
 
 
 
Time interview started: 
 
 
 
Time interview finished: 
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1. Unique ID…………….................... 
 
 
2.   Hospital number…………………… 
3.  Race………………………………… 
4.   Gender……………………………… 
5. Date of Birth……………………….. 
 
 
6. Baseline CD4 count……………… 
 
 
7. WHO staging………………………. 
 
 
8. Cell phone number………………… 
 
 
9. What is the highest level of education that you have successfully completed? 
 
 
Diplomas or certificates must be of six months 
Plus study duration full-time (or equivalent) to be 
Included 
98 = No schooling 
00 = Grade R/0 
01 = Grade 1/ Sub A/Class 1 
02 = Grade 2 / Sub B/Class 2 
03 = Grade 3/Standard 1/ ABET 1(Kha Ri Gude, Sanli) 
04 = Grade 4/ Standard 2 
05 = Grade 5/ Standard 3/ ABET 2 
06 = Grade 6/Standard 4 
07 = Grade 7/Standard 5/ ABET 3 
08 = Grade 8/Standard 6/Form 1 
09 = Grade 9/Standard 7/Form 2/ ABET 4 
10 = Grade 10/ Standard 8/ Form 3 
11 = Grade 11/ Standard 9/ Form 4 
12 = Grade 12/Standard 10/Form 5/Matric 
(No Exemption) 
13 = Grade 12/Standard 10/Form 5/Matric (Exemption *) 
14 = NTC 1/ N1/NC (V) Level 2 
15 = NTC 2/ N2/ NC (V) Level 3 
16 = NTC 3/ N3/NC (V)/Level 4 
17 = N4/NTC 4 
18 = N5/NTC 5 
19 = N6/NTC 6 
20 = Certificate with less than Grade 12/Std 10 
21 = Diploma with less than Grade 12/Std 10 
22 = Certificate with Grade 12/Std 10 
23 = Diploma with Grade 12/Std 10 
24 = Higher Diploma (Technicon/University of 
Technology) 
25 = Post Higher Diploma (Technicon/University of 
Technology Masters, Doctoral) 
26 = Bachelor’s Degree 
27 = Bachelor’s Degree and post-graduate diploma 
28 = Honor’s Degree 
29 = Higher degree (Masters, Doctorate) 
30 = other (specify in the box below) 
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10. Do you or anyone in your household receive a 
Social grant, pension or social relief 
Assistance from the Government? 
 
1 = Yes 
2 = No 
3 = Do not know 
 
 
 
11. During the last calendar week (Sunday to Saturday) 
Did you work for a wage, salary, commission or any 
payment in kind (including paid domestic work), 
even if it was for only one hour? Examples: a regular 
job, contract, casual or piece work for pay, work in 
exchange for food or housing, paid domestic work. 
 
1 = Yes 
2 = No 
3 = Do not know 
 
12. During the last calendar week (Sunday to Saturday) 
Did you run or do any kind of business, big or small, 
for yourself or with one or more partners, even 
if it was for only one hour? Examples: Commercial 
farming, selling things, making things for sale, construction, 
repairing things, guarding cars, brewing beer, collecting wood 
or water for sale, hairdressing, crèche businesses, taxi or 
other transport business, having a legal or medical practice, 
performing in public, having a public phone shop, etc. 
 
1 = Yes 
2 = No 
3 = Do not know 
 
 
13. What is your total salary/pay at your main 
job? Including overtime, allowances and bonus, 
before any tax or deductions. Give amount in 
whole figures, without any text or decimals. If 
“NONE”, “REFUSE” or “DO NOT KNOW write 
999 999 999 …………………… 
 
14. Ask only if an amount is given in Q11 
Is this …. 
 
1 = Per week 
2 = Per month 
3 = Annually 
 
15. What means of transport is usually used by 
you to get to your place of employment? If 
more than one mode is used, indicate the one 
that covers the longest distance. 
1 = Office is at home 
2 = Walking 
3 = Bicycle/motorcycle 
4 = Minibus taxi/ sedan taxi/bakkie taxi 
5 = Bus 
6 = Train 
 
 
 
 
http://etd.uwc.ac.za
76  
7 = Lift club by a group of people sharing a 
private vehicle 
8 = Own car/other private vehicle/company 
vehicle 
9 = Other (specify in the block) 
 
 
 
16. How many minutes does it take you to get to 
your place of employment? Specify for one 
direction only, using all the usual means of transport 
 
1 = Less than 15 minutes 
2 = 15 - 30 minutes 
3 = 31 - 60 minutes 
4 = 61 - 90 minutes 
5 = More than 90 minutes 
6 = Do not know 
 
 
17. During the last four calendar weeks, were you 
looking for any kind of job or trying to start 
any type of business? 
 
1 = Yes 
2 = No 
3 = Do not know 
 
18. What was the main reason for not trying to 
find work or starting a business during the 
past four calendar weeks? 
 
01 = Awaiting the season for work 
02 = Waiting to be recalled to former job 
03 = Health reasons 
04 = Pregnancy 
05 = Disabled or Unable to work (Handicapped) 
06 = Housewife/Homemaker (Family 
Considerations/child care) 
07 = Undergoing training to help find work 
08 = No jobs available in the area 
09 = Lack of money to pay for transport to look 
For work 
10 = Unable to find work requiring his/her skills 
11 = Lost hope of finding any kind of work 
12 = No transport available 
13 = Scholar or student 
14 = Retired 
15 = Too old/young to work 
16 = did not want to work 
17 = Other 
 
19. Did you own a mobile telephone in working 
Order during some or all of the past 12 months? 
 
1 = Yes 
 
2 = No 
 
20. Is this facility the nearest of its kind (clinic/hospital/health center 
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Etc.) To your dwelling? 
 
1 = Yes 
2 = No 
 
21. Answer if “No” in 18 
If not the nearest, why is the household normally not using the 
nearest facility? 
 
01 = Facilities not clean 
02 = Long waiting time 
03 = Opening times not convenient 
04 = Too expensive 
05 = Drugs that were needed, not available 
06 = Staff rude or uncaring or turned patient away 
07 = Incorrect diagnosis 
08 = Not on medical aid scheme list of facilities 
09 = Prefer to use a State/Provincial health institution 
10 = Prefer to use a private health institution 
11 = other (specify) 
 
 
 
22. What are the sources of income for this household? 
Read all the options 
 
1 = Salaries/wages/commission 
2 = Income from a business 
3 = Remittances (money received from people living elsewhere) 
4 = Pensions 
5 = Grants (include old age grant here) 
6 = Sales of farming products and services 
7 = other income sources e.g. rental income, interest 
8 = No income 
 
23. Which one of the above income sources is the main source of 
Income? 
Write the option number below. If only one source of 
Income write the code of that one source. 
 
24. If the household receives an income from remittances, please 
Specify approximately how much they receive per month? If no 
Income received from remittances write 0. 
 
 
25. If the household receives an income from pensions (do 
Not include income from old age grants), please specify 
Approximately how much they receive per month? If no income 
Received from pensions write 0. 
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Appendix 5: Tables of results 
 
Table 4.1 Demographic, socio-economic and clinical characteristics of the study population 
 
 
Demographic, socio-economic and clinical characteristics of the 106 participants in the study 
population. This population was divided into the group of 46 participants not yet eligible for ART 
(ART naïve) and 60 participants eligible to start ART (ART). 
 Total ART-naïve ART  
p-value (n= 106) (n= 46) (n= 60) 
n (%) n (%) n (%) 
Age, yrs., median (IQR) 36 (30-44) 34(27-43) 38 (32-46) 0.0084 
Gender     
<0.001 Female 74 (69.81) 42 (91.30) 32 (53.33) 
Males 32 (30.19) 4 (8.70) 28 (46.67) 
     
Education     
 
 
0.492 
No education 2 (1.89) 0 (0.00) 2 (3.33) 
Grade 1-7 18 (16.98) 13 (28.26) 5 (8.33) 
Grade 8-11 33 (31.13) 10 (21.74) 23 (38.33 
Grade 12 44 (41.51) 18 (39.13) 26 (86.67) 
>Grade 12 9 (8.49) 5 (10.87) 4 (6.67) 
     
Employment     
0.207 
Employed 64 (60.38) 25 (54.35) 39 (65.00) 
Self employed 7 (6.60) 4 (8.70) 3(5.00) 
Unemployed 35 (33.02) 17 (36.96) 18 (30.00) 
     
Income, median (IQR) 1500 (0-3800) 1650 (0-4500) 2218 (0-2218)  
≤R500 4 (5.63) 2 (6.90) 1 (2.38)  
 
0.896 
R550-R2000 18 (25.35) 6 (20.70) 13(30.95) 
R2500-R5000 23 (32.39) 12 (41.38) 11 (26.19) 
>R5000 6 (8.45) 5 (17.24) 1 (2.38) 
Did not want to disclose 20 (28.17) 4 (13.79) 16 (38.10) 
     
CD4 count, cell/mm³ median (IQR) 494.50 (155-680) 697.50 (589-900) 213.50 (80-387.50) <0.001 
≤200 29 (27.36) 0 (0.00) 29 (48.33)  
<0.001 
>201 - 350 12 (11.32) 0 (0.00) 12 (20.00) 
>351 - 500 12 (11.32) 0 (0.00) 12 (20.00) 
>500 53 (50.00) 46 (100.00) 7 (11.67) 
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Table 4.2 Health-related quality of life (EuroQol) of ART-naïve and ART groups at study baseline and ART baseline vs ART 2- 
3 months after study enrolment 
 
 
Analysis using Pearson's chi-square (χ2), Fischer's exact test for number of observations per cell of less than 5, as well as t-test 
for continuous variables were undertaken. 
 Baseline 2-3 months follow-up 
 
 
Total 
ART-naïve 
(study 
baseline) 
ART 
(study baseline) 
 
 
P value 
ART 
(study 
baseline) 
ART 
(2-3 months 
follow-up) 
 
 
P value 
 n=106 n=46 n=60 n=60 n=59 
 N (%) N% N% N% N% 
Mobility        
No problems 92 (86.79) 40 (86.96) 52 (86.67) 
0.965 
52 (86.67) 58 (98.31) 
1 (1.69) 0.011 Problems 14 (13.21) 6 (13.04) 8 (13.33) 8 (13.33) 
        
Self Care        
No problem 103 (97.17) 46 (100) 57 (95.00) 
0.256 
57 (95.00) 59 (100.00)  
N/A Problems 3 (2.83) 0 (0.00) 3 (5.00) 3 (5.00) 0 (0.00) 
        
Usual Activities        
No problems 93 (87.74) 44 (95.65) 49 (81.67) 
0.037 
49 (81.67) 56 (94.92)  
0.086 Problems 13 (12.26) 2 (2.00) 11 (18.33) 11 (18.33) 3 (5.08) 
        
Pain/Discomfort        
No problems 63 (59.43) 27 (58.70) 36 (60.00) 
0.892 
36 (60.00) 49 (83.05)  
0.005 Problems 43 (40.57) 19 (41.30) 24 (40.00) 24 (40.00) 10 (16.95) 
        
Depression/Anxiety        
No problems 81 (76.42) 34 (73.91) 47 (78.33) 
0.595 
47 (78.33) 50 (84.75)  
0.008 Problems 25 (23.58) 12 (26.09) 13 (21.67) 13 (21.67) 9 (12.25) 
        
Index Score (IQR) 0.88 (0.81-0.90) 0.86 (0.81-0.90) 0.90 (.81-.90) 0.705 0.90 (.81-.90) 0.90 (0.86-0.90) 0.0001 
VAS score, median (IQR) 80 (65-93) 66.50 (60-80) 90 (76.50-99.00) <0.001 90 (76.50-99.00 98 (90.00- 100.00) <0.001 
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Table 4.3 univariate and Multivariate analyses showing factors associated with the five Health related Quality of Life (EuroQol) domain s 
 
Univariate analysis indicated no difference in HRQoL in all domains of HRQoL. 
 
The multivariate analysis indicate that ART naïve group is less likely to experience problems with pain/discomfort and Anxiety/depression 
Variable 
Mobility Usual  activities Pain/discomfort Anxiety/depression 
IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value IRR (95% CI) p-value aRR (95% CI) p-value 
Age 1.00 (.99-1.00) 0.668 0.99 (0.99-1.00) 0.159 1.00 (1.00-1.00) 0.763   1.01 (1.00-1.01) 0.064 1.00 (1.00-1.01) 0.29 1.00 (1.00-1.01 0.356 1.00 (0.99-1.00) 0.899 
Gender                 
Female 1.00 (1.00-1.00)                
Males 0.91 (0.86-0.97) 0.004 0.98 (0.93-1.03) 0.356 1.02 (0.93-1.12) 0.629 1.03 (0.93-1.15) 0.592 0.88 (0.76-1.10) 0.062 0.97 (0.89-1.07) 0.576 1.00 (0.86-1.16) 0.987 1.08 (0.96-1.21) 0.217 
                 
Education                 
No education 1 (1-1) 0.988               
>Grade 12 1.75 (1.02-1.129) 0.005 1.05 (0.95-1.17) 0.338 0.94 (0.78-1.13) 0.511 0.92 (0.78-1.08) 0.301 1.04 (0.83-1.32) 0.716 1.01 (0.91-1.11) 0.88 1.1 (0.90-1.34) 0.902 1.04 (0.85-1.27) 0.69 
≤Grade 12 1 (1-1) 0.988 1.03 (0.86-1.23) 0.771 0.90 (0.75-1.05 0.266 0.83 (0.68-1.02) 0.723 1.23 (.73-2.05) 0.436 1.12 (.82-1.54) 0.471 0.9 (0.75-1.08) 0.266 0.97(0.76-1.25) 0.836 
                 
Employment                 
Employed 1 (1-1)                
Self employed 0.96 (0.91-1.00) 0.071 0.98 (0.89-1.08) 0.649 0.94 (089.1.00) 0.034 0.95 (0.86-1.05) 0.303 1.02 (0.77-1.34) 0.911 1.07 (0.87-1.32) 0.521 1.04 (0.79-1.36) 0.805 1.04 (0.85-1.28) 0.677 
Unemployed 1.07 (0.96-1.19) 0.241 1.08 (0.98-1.18) 0.122 0.97 (.90-1.05) 0.432 0.99 (0.91-1.08) 0.767 1.02 (0.88-1.18) 0.766 1.04 (0.93-1.17) 0.446 0.91 (0.79-1.04) 0.148 0.91 (0.82-1.01) 0.787 
                 
ART status                 
ART 1 (1-1)                
ART-naïve 1.11 (1.01-1.22) 0.025 1.08 (0.96-1.22) 0.183 0.99 (0.92-1.07) 0.86 1.01 (0.96-1.07) 0.665 1.21 (1.06-1.38) 0.004 1.10 (0.99-1.21) 0.655 1.08 (0.95-1.24) 0.233 0.84 (0.76-0.93) 0.001 
                 
CD4 count                 
≤200 1 (1-1) 0.999               
>201 - 350 1 (1-1) 0.999 1.07 (0.97-1.17) 0.169 0.91 (0.82-1.00) 0.056 0.91 (0.81-1.02) 0.101 0.85 (0.70-1.03) 0.976 0.90 (0.79-1.03) 0.12 1.01 (0.81-1.26) 0.921 1.01 (0.85-1.18) 0.949 
>351 - 500 1.09 (0.93-1.26) 0.276 1.14 (0.99-1.32) 0.07 0.91 (0.82-1.00) 0.056 0.91 (0.79-1.050 0.188 0.86 (0.70-1.05) 0.129 0.86 (0.72-1.04) 0.115 1.10 (0.87-1.40) 0.424 1.05 (0.86-1.28) 0.647 
>500 1.11 (1.03-1.20) 0.006 1.13 (0.95-1.35) 0.18 0.94 (0.84-1.05 0.285 0.94 (0.79-1.11) 0.438 1.06 (0.91-1.25) 0.441 0.85 (0.67-1.09) 0.212 1.07 (0.92-1.24) 0.408 0.89 (0.72-1.10) 0.289 
                 
IRR - Univariate Incident Rate Ratio                
aIRR- Multivariate Incident Rate Ratio               
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Table 4.4 A sub-analysis of the ART and ART naïve groups on the difference between male and female VAS responses 
 
The results for each analysis indicates that there is no statistically significant difference in the baseline VAS score mean 
for males and females for all study patients (p=0.3145). There is also no difference in the baseline VAS score mean for 
males and females among the ART patients (p=0.4867) 
 Baseline 
  
Total 
 
 
P value 
ART-naïve 
(study 
baseline) 
 
 
P value 
ART 
(study baseline) 
 
 
P value 
 n=106 n=46 n=60 
 N (%) N% N% 
VAS score, median (IQR) 80 (65-93)  66.50 (60-80)  90 (76.50-99.00) <0.001 
Males 32 (30.19) 
0.315 
4 (8.70)  
0.487 
28 (46.67) 
0.678 
Females 74 (69.81) 42 (91.30) 32 (53.33) 
 
 
 
 
 
Table 4.5 Income of ART group at baseline and 2 to 3 months post initiation. 
 
The analysis looks at the income of ART group at baseline then 2-3 months post ART initiation, 
there was a significant change income 2-3 months post ART initiation. 
  
ART 
(study baseline) 
 
ART 
(2-3 months post ART 
initiation) 
 
 
P value 
 
 
Income median (IQR) 2218.32  (1727.88-2709.39) 2464.87  (1983.05-2946.70) 0.013 
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